Patent Grant
12207901
The present application relates generally to the fields of detection of malaria parasites in a patient's body, in particular, with the use of laser-induced transient vapor nanobubbles.
Malaria is a widespread and infectious disease that can cause serious illness and death in humans. A patient can be infected when a malaria parasite infects cells of the patient, also known as a host. The parasite can produce Hemozoin, which are nanocrystals formed when the parasite digests the hemoglobin in the host's red blood cells. Malaria-infected red blood cells or other body tissue infected by malaria parasites contain Hemozoin nanocrystals.
Current malaria diagnosis techniques include, for example, rapid diagnostic tests (RDTs), microscopy, and polymerase chain reaction (PCR). These diagnosis techniques analyze a patient's blood samples. RDT analyzes the proteins in the blood to look for presence of malaria parasites and is approved by the World Health Organization (WHO). Microscopy uses stain of a thick blood slide, such as with a 200 to 500 white blood cell count, to determine malaria parasite density and gametocyte counts. Microscopy is also WHO-approved for malaria diagnosis. PCR analyzes DNAs in the blood to determine presence of malaria parasites.
Malaria can be treated and/or prevented by administration of antimalarial drugs, such as quinine, chloroquine, atovaquone/proguanil, and others.
Laser-induced transient vapor nanobubbles can be used to diagnose malaria. The diagnosis can be in a noninvasive, efficient, and/or reproducible manner. The transient vapor nanobubbles can be generated around one or more malaria-specific nanoparticles, that is, one or more Hemozoin nanocrystals (with or without an active malaria parasite) when laser pulses are applied to the nanoparticles. In some embodiments, malaria-specific nanoparticles may also optionally be introduced into the host red blood cells. The laser pulses can cause rapid heating of the malaria-specific nanoparticles, but not of uninfected red blood cells or other host tissues. Liquid (such as water) around the malaria-specific nanoparticles can rapidly evaporate, leading to the generation of a transient vapor nanobubble.
The generation of transient vapor nanobubbles can be detected by optical detectors. A transient vapor nanobubble in a condensed media (such as liquid or skin or their mixture) can act as an optical reflector or scatterer as the vapor-skin boundary creates a relatively high gradient in the optical refractive index in the medium. Throughout the disclosure, scattering of light can refer to the scattering, reflecting, and/or deflecting of light. Therefore, a transient vapor nanobubble can scatter or reflect or deflect an incident (probe) light. The amount of scattered light can be determined by the maximal diameter of the transient vapor nanobubble. That is, the optical energy or power scattered by the transient vapor nanobubble follows the expansion and collapse dynamics of the transient vapor nanobubble. If the light scattered or reflected by such a transient vapor nanobubble is collected and detected as an optical signal, the signal can contain information about the expansion and collapse of the transient vapor nanobubble. A nanobubble-specific optical signal can include a signal time-shape reflecting the expansion and collapse of a transient vapor nanobubble during its lifespan. A transient vapor nanobubble, such as one generated around Hemozoin nanocrystals, can have a lifespan from about 10 ns to about 10 us.
The transient vapor nanobubbles can be generated using a laser pulse that optically excites the Hemozoin (HZ) in a liquid sample (such as blood, in particular peripheral blood, or urine) or skin. The Hemozoin-generated vapor nanobubbles in the liquid sample or the patient's skin can be detected by detecting the optical scattering of the probe light by the vapor nanobubbles. The optical detection examples disclosed herein can detect HZ-generated transient vapor nanobubbles in an optically turbid media (for example, the skin, blood, or otherwise).
In some embodiments, the transient vapor nanobubble-based malaria detection mechanism can detect a single Hemozoin nanoparticle. The transient vapor nanobubble-based optical malaria detection mechanism disclosed herein can be advantageous over the bulk photoacoustic optical scattering mechanism, which requires a large number of Hemozoin nanoparticles and high excitation optical energies to produce a detectable malaria-positive optical signal and may not be sensitive enough to detect a single parasite. In addition, a vapor nanobubble can produce much stronger optical scattering. The optical detection examples disclosed herein can detect Hemozoin-generated transient vapor nanobubbles at any type and/or stage of malaria at which the patient's body contains Hemozoin. The transient vapor nanobubble-based malaria detection mechanism disclosed herein can improve the sensitivity and/or selectivity of the detection of malaria parasites. The transient vapor nanobubble-based malaria detection mechanism disclosed herein can allow detection of malaria via a noninvasive and/or a non-contact manner. That is, the hardware of the optical detection system needs not contact the test sample, such as the patient's skin or a flow of blood.
The optical detection method can have advantages of the acoustic detection method, which is described in U.S. application Ser. No. 16/213,923. Advantage of optical detection over acoustic detection can include higher sensitivity and/or selectivity, lower noise, and/or false-positive signals. However, the optical detection systems and methods disclosed herein may also result in a reduction of the probed volume and therefore require increasing the number of tests in different locations, compared to the acoustic detection of Hemozoin-generated transient vapor nanobubbles.
In some embodiments, a non-invasive malaria sensor can use both acoustic (ultrasonic) and optical detection simultaneously.
A system configured to detect malaria noninvasively can comprise a laser pulse source configured to provide a laser pulse to a measurement site, the laser pulse configured to generate a transient vapor nanobubble around a malaria-specific optically absorbing nanoparticle, if present, located at a depth in the measurement site; a probe light source configured to provide a probe light to the measurement site, the probe light configured to be scattered, reflected, and/or deflected by the transient vapor nanobubble; and a photodetector configured to detect the scattered, reflected, and/or deflected probe light and output a nanobubble signal comprising characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble.
In some embodiments, the system can comprise one or more lenses configured to focus the probe light into the measurement site. In some embodiments, the system can comprise a plurality of free-space optics to direct paths of the laser pulse, the probe light, and the scattered, reflected, and/or deflected probe light. In some embodiments, the system can comprise a plurality of optical fibers to direct paths of the laser pulse, the probe light, and the scattered, reflected, and/or deflected probe light. In some embodiments, the laser pulse can be delivered to the measurement site in a multi-mode optical fiber. In some embodiments, the multi-mode optical fiber can have a core diameter of about 100 um to about 200 um. In some embodiments, the probe light can be delivered to the measurement site in a single-mode optical fiber. In some embodiments, the single-mode optical fiber can have a core diameter of about 5 um to about 10 um. In some embodiments, at least one of the optical fibers can comprise a distal tip engineered to concentrate optical energy into the measurement site through a lens, taper, a mirror, or any combinations thereof. In some embodiments, the laser pulse can have a wavelength of 671 nm or 672 nm. In some embodiments, the laser pulse can have a duration of about 300 ps. In some embodiments, the laser pulse can have an energy of about 20 uJ. In some embodiments, In some embodiments, the probe light source can comprise laser. In some embodiments, the probe light can comprise a non-coherent light. In some embodiments, the probe light source can comprise a super luminescent diode. In some embodiments, the probe light can have a wavelength of 1310 or 785 nm. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a dip or arch shape in the signal responsive to at least a first laser pulse. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a decay in the signal amplitude responsive to one or more laser pulses after the first laser pulse. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a malaria-positive threshold calculated based in part on sample-averaged metrics of the signals. In some embodiments, the system can be configured to detect malaria without any hardware of the system contacting the measurement site. In some embodiments, the system can have a sensitivity of being able to detect a transient vapor nanobubble of or smaller than 100 ns in lifetime. In some embodiments, the measurement site can comprise a patient's skin. In some embodiments, the depth can be about 200 um to about 500 um. In some embodiments, the measurement site can comprise a patient's physiological fluid including blood, urine, interstitial body fluid that has been drawn from the patient. In some embodiments, the system further can comprise a static filter for holding the physiological fluid. In some embodiments, the system further can comprise a microfluidic device configured to receive a flow of the physiological fluid.
An optical sensor configured to detect malaria noninvasively can include a laser pulse source configured to deliver a pump laser pulse to a measurement site to excite a malaria-specific nanoparticle at a depth of the measurement site to generate a transient vapor nanobubble around the malaria-specific nanoparticle; a first optical fiber configured to deliver a probe light to be scattered by the transient vapor nanobubble; a second optical fiber configured to collect and direct the scattered probe light; and a photodetector coupled to the second optical fiber at a location proximal to a distal end of the second optical fiber, the photodetector configured to detect the scattered/reflected/deflected probe light and output a nanobubble signal comprising characteristics of optical scattering by the transient vapor nanobubble.
In some embodiments, the sensor can comprise a sensor housing, wherein one or more of the optical fibers are enclosed within the sensor housing. In some embodiments, the sensor can comprise a third optical fiber configured to direct the laser pulse to the measurement site. In some embodiments, the pump pulse delivery optical fiber can be located within a sensor housing. In some embodiments, the third optical fiber can be configured to deliver the laser pulse to the measurement site. In some embodiments, the first or second fiber can be configured to direct the laser pulse to the measurement site. In some embodiments, the second optical sensor can comprise a lensed tip. In some embodiments, the second optical fiber can have a core diameter of about 200 um. In some embodiments, the second optical fiber can comprise a multi-mode fiber. In some embodiments, the first optical fiber can comprise a single-mode optical fiber. In some embodiments, the first optical fiber can have a core diameter of about 5 um. In some embodiments, the first optical fiber can comprise a lensed distal tip. In some embodiments, distal ends of the first and second optical fibers can be at a predetermined angle from each other. In some embodiments, one of the first or second optical fibers can comprise recess cladding to reduce the angle. In some embodiments, distal ends of the first and second optical fibers can run substantially parallel to each other. In some embodiments, the probe light can be emitted by a super luminescent diode. In some embodiments, the first and second optical fibers can comprise front input and front output. In some embodiments, the first and second optical fibers can comprise side input and side output. In some embodiments, the sensor can comprise a lens at an area of optical input and output. In some embodiments, the first and second optical fibers can be aligned such that an input light path and an output light path coincide. In some embodiments, the characteristics of optical scattering/reflection/deflection by the transient vapor nanobubble can comprise a dip or arch shape in the signal responsive to at least a first laser pulse. In some embodiments, the characteristics of optical scattering/reflection/deflection by the transient vapor nanobubble can comprise a decay in the signal amplitude responsive to one or more laser pulses after the first laser pulse. In some embodiments, the characteristics of optical scattering/reflection/deflection by the transient vapor nanobubble can comprise a malaria-positive threshold calculated based in part on sample-averaged metrics of the signals. In some embodiments, the sensor can be configured to detect malaria without contacting the measurement site. In some embodiments, the sensor can have a sensitivity of being able to detect a transient vapor nanobubble of or smaller than 100 ns in lifetime. In some embodiments, the measurement site can comprise a patient's skin. In some embodiments, the depth is about 200 um to about 500 um.
A method of detecting malaria noninvasively can comprise driving a laser pulse source to apply a plurality of laser pulses to a plurality of locations at a measurement site, the laser pulse configured to generate a transient vapor nanobubble around a malaria-specific optically absorbing nanoparticle, if present, located at a depth in the measurement site; driving a probe light source to apply a probe light to the plurality of locations, the probe light configured to be scattered, reflected, and/or deflected by the transient vapor nanobubble; receiving a plurality of optical signals from a photodetector detecting the probe light scattered, reflected, and/or deflected by the transient vapor nanobubble at the plurality of locations; and determining whether the measurement site is malaria-positive by: determining electronically a first signal amplitude or area of each of the plurality of optical signals responsive to a first laser pulse and a subsequent laser pulse at each location; calculating electronically a decay value between the optical signal responsive to the first laser pulse and the optical signal responsive to the subsequent laser pulse at each location; applying a statistical analysis to a distribution of the first signal amplitude or area and the decay value for the plurality of locations; and outputting a malaria-positive diagnosis threshold.
In some embodiments, the decay value can be calculated as a ratio of the first signal amplitude or area to a subsequent signal amplitude or area. In some embodiments, the optical signal can be analyzed in a pre-determined time window. In some embodiments, a ratio of two signal amplitudes or areas can be calculated for two pre-determined time-windows. In some embodiments, one of the plurality of locations can be 1.5 times of a diameter of the laser pulse away from another one of the plurality of locations. In some embodiments, the statistical analysis can comprise determining a preliminary threshold based on the distribution of the first signal amplitude or area and the decay value for the plurality of locations in known malaria-free samples. In some embodiments, the statistical analysis can comprise calculating a probability value of signals from known malaria-positive samples exceeding the preliminary threshold. In some embodiments, the statistical analysis further can comprise determining an amplitude or area threshold and a decay value threshold only for the signals in the known malaria-positive and malaria-free samples that exceed the preliminary threshold. In some embodiments, the statistical analysis further can comprise comparing the probability value, the amplitude or area threshold, and the decay value threshold for the signals from the known malaria-free samples and the signals from the known malaria-positive samples. In some embodiments, the amplitude or area of the signal can be determining after removing a background level.
A system for detecting malaria parasites or Hemozoin nanoparticles in a fluid from a patient, the fluid comprising the patient's blood, urine, interstitial fluid or other physiological liquid, can comprise a micro-fluidic device configured to receive a flow of the fluid from the patient; a laser pulse source configured to provide a laser pulse to the flow of the fluid from a first side of the micro-fluidic device, the laser pulse configured to generate a transient vapor nanobubble around a malaria-specific nanoparticle, if present, located in the patient's blood; a probe light source configured to provide a probe light to the flow from the first side of the micro-fluidic device, the probe light configured to be scattered, reflected, and/or deflected by the transient vapor nanobubble; and a photodetector located at a second side of the micro-fluidic device opposite the first side, the photodetector configured to detect the scattered, reflected, and/or deflected probe light and output a nanobubble signal comprising characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble.
In some embodiments, the micro-fluidic device can be connected to a pump with a syringe containing the fluid. In some embodiments, the pump can be configured to pump the fluid at a flow rate of about 0.2 uL/min to about 0.4 uL/min. In some embodiments, the micro-fluidic device can comprise a plurality of micro-cuvettes. In some embodiments, the pump laser pulse and the probe light can be directed to the flow of the patient's blood in the micro-cuvette. In some embodiments, the micro-cuvette can comprise a glass capillary having an inner diameter of about 50 um to about 100 um. In some embodiments, the laser pulse can have a wavelength of about 672 or 671 nm. In some embodiments, the pump laser pulse can have a fluence level of about 100 mJ/cm2 to about 500 mJ/cm2. In some embodiments, the probe light can comprise laser. In some embodiments, the probe light can comprise an incoherent light. In some embodiments, the probe light can be emitted by a super luminescent diode. In some embodiments, the probe light can have a wavelength of about 632.8 or 785 nm. In some embodiments, the probe light can have an energy level of about 1 to 30 mW. In some embodiments, the system can further comprise a single-mode optical fiber configured to deliver the probe light. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a dip or arch shape in the signal responsive to at least a first laser pulse. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a decay in the signal amplitude responsive to one or more laser pulses after the first laser pulse. In some embodiments, the characteristics of optical scattering, reflecting, and/or deflecting by the transient vapor nanobubble can comprise a malaria-positive threshold calculated based in part on sample-averaged metrics of the signals. In some embodiments, the system can have a sensitivity of being able to detect a transient vapor nanobubble of or smaller than 100 ns in lifetime.
Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. In addition, various features of different disclosed embodiments can be combined to form additional embodiments based on the present disclosure, which are part of this disclosure. Features in the drawings are not necessarily shown to scale.
Overview of Example Systems and Processes of Detecting Transient Vapor Nanobubbles by Optical Detection
A transient vapor nanobubble, such as a Hemozoin-generated vapor nanobubble, may be detected by detecting the optical scattering, reflecting, and/or deflecting by the vapor nanobubble (Signal S1 in
An optical detection of pressure gradients of acoustic waves generated by the vapor nanobubble is based on the related changes of optical refractive index of the skin as the acoustic pulse from a vapor nanobubble propagates through the skin. When a transient pressure gradient travels through the optically probed volume, the optical scattering of the pressure pulse will change due to the change in pressure-dependent optical refractive index. On the detector end, such change can produce a signal S2, which is a deviation from a baseline. S2 can be stronger than S3.
However, a better (stronger) signal S1 can be obtained through the direct optical detection of the vapor nanobubble: its vapor (inside a nanobubble)-skin (outside nanobubble) boundary scatters, reflects, and/or deflects the light much stronger than the acoustic wave. This is because such a boundary creates a stronger gradient of the optical refractive index than the gradient created by the acoustic waves (generated with any opto-acoustic method). Hence, the direct optical detection of a Hemozoin-generated vapor nanobubble can be a more sensitive approach for the malaria detection than the pressure pulse based detection methods. Since the excitation (pump) laser pulse can be delivered to a parasite, a continuous probe laser beam can also be delivered to the same parasite. A portion of the probed laser beam will be backscattered (including scattering, reflecting, and/or deflecting). The backscattered component, collected with a high numerical aperture (NA) lens, can be depth-specific so that it is possible to analyze the light backscattered within a specific focal volume (including a specific skin depth range). This backscattered light creates a baseline. A vapor nanobubble can enhance the optical scattering and produces a specific time-response signal. The present disclosure is related to the direct optical detection method of malaria.
If the skin tissue 10 is or has been infected by malaria parasites, the skin tissue 10 can contain the malaria parasite 20 or Hemozoin nanocrystals. The pump beam 100 can generate a transient vapor nanobubble around the parasite 20 or the Hemozoin nanocrystals. The pump beam can optionally be applied in sequence (in a series of pulses) to the skin tissue 10.
The system can have a second optical source to produce a probe beam 102, which may be another laser beam (continuous or pulsed), or a non-coherent light generated by a light-emitting diode, or otherwise. The probe beam 102 can be directed to the same location where the pump beam has been directed in the skin 10. An optical detectors 104, such as a photodetector, can be configured to detect the probe beam 102 scattered by the transient vapor nanobubble through the optical elements that collect the probe light scattered by Hemozoin-generated vapor nanobubble (HVNB). When a probe beam 102 is delivered to the skin, there can be a plurality of sources of optical scattering, which can include, for example, background scattering by the skin tissue, scattering by acoustic waves in tissue (which may be in different densities and therefore resulting in different pressure-induced gradients of refractive index), and/or optically scattering by the Hemozoin-generated vapor transient nanobubble. The boundary between the Hemozoin-generated vapor transient nanobubble and the tissue can result in a refractive gradient that causes an optical scattering in a stronger way than acoustic waves or thermal fields. The system disclosed herein can detect the optical scattering by the Hemozoin-generated vapor transient nanobubble in the skin.
The probe beam 102 can have a wavelength (for example, in the near-infrared region or otherwise) so as to penetrate through a certain depth of the skin (for example, up to 1 mm). The diameter of the probe beam 102 can be kept small, as will be described below, (thereby making the probe beam more focused) to improve the sensitivity of the optical detection system. A more focused probe beam with a more restricted focal volume, when optically coupled (that is, projected) into the plane of the optical detector, can help to reject all or substantially all of the scattering effects coming from outside of the focal volume. This can improve the selectivity of the HVNB detection in presence of a photo-thermal and photoacoustic background not related to malaria parasites and HZ, allowing such background to be spatially separated from the focal volume of the optical system.
As the delivery and collection of probe beam or light 102 occurs in a highly optically turbid and scattering medium, that is, the skin or blood, with significant losses in both illumination and collection optical paths, the medium can result in an optical noise in the optical signal. A combination of optical power in the probe beam sufficient to penetrate to and from the skin (such as in the order of milliwatts) with reduction in noise at both the light source and the optical detector can help to improve the signal-to-noise ratio and/or improve detection of nanobubble-induced deviation of the signal from its baseline, which is formed by the optical scattering by the skin tissue within the focal volume.
The system can have one or more signal processors and/or controller in electrical communication with the optical sources and/or the optical detector 104. The one or more signal processors can process optical signals 106 from the optical detector 104 to determine if the signals are indicative of transient vapor nanobubble(s) generation and thus for the presence of Hemozoin nanocrystals.
As shown in
The sensor can be temporarily attached to the patient at the measurement site via any suitable coupling mechanisms, including but not limited to an elastic bracelet, straps, adhesives, clamps, suction device, and/or the like. The attachment can optionally include a reversible locking mechanism. The attachment can be different for various anatomical locations. The sensor and/or the sensor and the interface layer can be reusable. The temporarily attachment mechanism can optionally be a single use component. In some embodiments, the temporary attachment can allow the sensor to be used without an operator holding onto the sensor to maintain the contact and/or optical coupling between the sensor and the skin. The attachment can provide a pressure between the skin surface and the sensor, for example, in the range of about 10-200 grams. The attachment of the sensor and signal collection can be performed within 0.1-5 minutes, or within 1-2 minutes.
The malaria sensor may optionally have a sensor casing. The casing can make the sensor for durable, more suitable for repeated use, and/or protect the components of the sensor from the elements, infection, electromagnetic interference, and/or others. The casing can include a relieve for optical and/or electrical cables.
The signals 110, 112, 114 also showed decay in the amplitude of the malaria-specific signal spike after each consecutive laser pulse. Additional details about the example optical signals are provided below.
Turning to
A combination of lenses (free space or combined with fiber optics) can be used to optically match the location of the skin volume of the transient vapor nanobubbles generation to the optical detector can improve the detection sensitivity of the Hemozoin-generated transient vapor nanobubbles and the rejection of the background photothermal effects. As will be described in greater detail below with reference to
The pulsed pump beam and the probe beam can have different wavelengths. In some embodiments, the pump beam 300 can have a wavelength of about 671 nm or about 672 nm. In some embodiments, the probe beam can have a wavelength of about 1300 nm to about 1310 nm, or about 600 nm to about 1,000 nm, or about 700 nm to about 900 nm, or about 660 nm, or about 930 nm, or about 1310 nm. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments. The probe beam wavelength can be selected so as to more easily propagate in the skin (or less attenuation) and to be closer to the excitation or pump beam wavelength to simplify management of hardware. The probe beam can be delivered constantly and/or in a train of pulses for periodic illumination. The laser pulses for Hemozoin-generated vapor transient nanobubble generation can be in the scale of nanoseconds or picoseconds. The signals relevant for detecting presence of malaria can therefore be significantly less affected or substantially unaffected by motion artefacts. In some embodiments, the probe beam can be emitted by an LED (that is, being non-coherent).
In some embodiments, the skin-specific focusing of the pump beam can be to a depth range of about 200 um to about 600 um to achieve an optical excitation volume having a diameter of about 20 um to about 100 um and/or a depth of about 20 um to about 500 um. In some embodiments, the skin-specific focusing of the probe beam can be to a depth range of about 100 um to about 500 um to achieve an optical detection volume having a diameter of about 5 um to about 50 um and/or a depth of about 100 um to about 500 um. Such an optical detection volume can be more optimal in rejecting potential false-positive signals generated by the photo-thermal or photoacoustic responses of non-malaria components in skin, such as melanin or otherwise. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
To detect malaria parasites in skin, a sufficient number of skin locations may need to be probed, for example, up from 2-3 to several hundreds, to scan the total volume of skin from about 0.01 uL3 to about 1 uL3. The required scanning can be done through the optical scanning of the pump and probe beams across the sample (such as the skin or liquid surface). The scanning may be also performed mechanically by shifting of the probes temporarily and operably attached to the sample.
Examples of Optical Delivery
The delivery of the pump beam and the probe beam in an optical detection system can be configured to reduce background skin optical noise (such as due to melanin). The delivery of the pump beam and the probe beam can minimize the optical fluence and the associated thermal impact of the background (for example, the melanin located at the upper level of the skin) and/or maximize the optical fluence at the depth of parasites. The probe beam can be focused. The probe beam can also be launched at an angle to the skin surface, with the pump beam angled from one side and the probe beam angled from an opposing side, so that the background skin volume is spatially decoupled from the skin volume with Hemozoin and/or parasites.
The background source, such as the melanin, is usually located in the upper skin layer, whereas the parasites are usually located about 100 um to about 500 um deeper in the upper skin layers. Although the melanin layer still produces some photo-thermal and/or photoacoustic background signals, the source of such background signal is shifted away from the axis of the detection of the transient nanobubble signal. The amplitude of the background signal can also be reduced due to a reduced optical fluence of the pump beam, that is, the excitation laser beam, at the level of the melanin layer.
Such spatial decoupling of the target (Hemozoin) and background (melanin) was validated in dark human skin (rich with melanin) and human parasites placed at the depth of about 250 um to about 300 um below the skin surface. The improvement in the side and focused launch of the pump beam compared to the standard fiber launch from substantially directly above the probe beam, can include an about 3 fold (such as a 3.2 fold) suppression of the background signal amplitude, and/or an about 2 fold (such as 1.8 fold) increase in a second spike with amplitude indicative of Hemozoin-generated transient vapor nanobubble.
An embodiment of the optical detection system disclosed herein can include free-space optics, fiber optics, and/or a combination of fiber optics and free-space optics.
In some embodiments, the pump beam 300 path can optionally be delivered by an optical fiber (for example, a multimode fiber) connected to an FC/PC connector C2. The optical fiber for delivering the pump beam or pump laser pulse 300 can include a step index optical fiber. The pump beam optical fiber can have a core diameter of about 60 um to about 200 um. The selected core diameter can reduce optical damage to the pump beam fiber. An input optical coupler (that is, coupling lens(es)) can be defocused so the optical fiber tip is placed past the pump beam waist and receives a diverging beam. The pump beam diameter can be about 80% of the pump beam optical fiber core diameter when the pump beam 300 enters the optical fiber. Optionally, high-energy ferrules with air gap around the fiber tip can also be included.
Additionally, so called “hot spots” in the pump beam can cause additional false-positive signals generated by melanin. These hot spots can be suppressed to improve the optical delivery. The pump beam optical fiber, which can be a mulita-mode optical fiber, can have an increased length of about 12 m from about 1-2 m, which may improve homogenizing of the pump beam intensity profile at the fiber output so as to reduce hot spots in the pump beam. Additional details of the “hot spots” are described in U.S. application Ser. No. 16/213,923.
The pump beam 300, upon exiting the optical fiber, can travel though Lens L4 and be deflected to Lens L2 by the mirrors M1 and M3. Lens L4 can be a collimator configured to output the pump beam 302 as parallel collinear beams. The diameter of the pump beam 300 can be between about 40 um to about 50 um before arriving at the mirror M1. The mirror M1 can be a pump beam mirror. The mirror M3 can be a beam-mixing mirror. At the skin entrance plane, that is, after being deflected by the mirror M3, the diameter of the pump beam 300 can be about 150 um to about 200 um. Lens L2 can be a working lens that re-focuses the pump beam 300 to the target site, for example, where the parasite and/or Hemozoin is located, in the skin 10. Lens L2 can be a condenser lens. Lens L2 can be also an aspheric lens. If the malaria parasite and/or Hemozoin are present in the skin 10, a transient vapor nanobubble 20 can be generated. The pump beam can be focused at about 40 mm under a surface of the target site, such as when the target site is water.
In some embodiments, the probe beam 302 path can travel along another optical fiber. The optical fiber coupled to the probe beam 302 can include, for example, a single mode fiber with a core diameter of about 9.5 um (or from about 4 um to about 10 um), via the FC/PC connector C1. Upon exiting the single mode optical fiber, the probe beam 302 can travel though Lens L1, an opening in the mirror M2, and Lens L2. Lens L1 can be a probe beam collimator that can output the probe beam 302 as parallel collinear beams. Lens L1 can have an adjustable focal distance. The working Lens L2 can focus the probe beam 302 to the target site 20. If the vapor transient nanobubble has been generated, the nanobubble can scatter the probe beam 302 as described above. The probe beam 302 path can be adjusted through Lens L1 and the vertical position Z of the optical detection system.
The illumination of the volume in the test sample, such as in the skin or liquid, by the probe beam 302 can be increase or maximized to improve detection sensitivity. This can be achieved by focusing the probe beam 302 using the working Lens L2 and by positioning Lens L2 at a specific distance from the skin or liquid surface so that its focus is set at the depth of about 250 um to about 500 um, where parasites and Hemozoin are expected in the skin. The working focal distance, which can be from the vapor transient nanobubble to a flat surface of the working Lens L2, can be from about 5 mm to about 15 mm.
The collection path of the scattered probe beam 303, such as illustrated in
Additional optional non-limiting specifications of the various optics components shown in
The collection of the scattered probe beam 303 can be improved directly by increasing and/or maximizing the collection of the probe beam scattered by the transient vapor nanobubble, and/or indirectly by reducing and/or minimizing the collection of background light scattered by the skin surface and the skin volume in the optical focus of the working lens L2. The direct improvements can be achieved by, for example, using a working Lens L2 with the maximal optical numerical aperture NA, and/or optically coupling the position of the photodetector and the transient vapor nanobubble so that both are located in matching optical foci of the optical collection system including Lenses L2 and L3. The indirect improvements can be achieved by using spatial filtering in the focus of the photodetector Lens L3, with an adjustable (x, y, z) pinhole having a diameter of about 10 um to about 100 um diameter in the focus of the lens L3 and/or in front of the photodetector.
Factors influencing the signal amplitude Avnb of a transient vapor nanobubble that is detected by the photodetector 307 can be related to the probe beam illumination, the collection, and/or the nanobubble size. The amplitude Avnb can be calculated using the formula Avnb=Pled×Killumination×Kcollection×Knanobubble. In the formula, K denotes an optical coupling factor. Killumination can include the optical intensity delivered through the skin, which can depend on the skin depth H, and the diameter of the focal spot in water DO created by the working Lens L2 (the lens in front of the water or skin). Kcollection can include the numerical aperture of the collecting Lens L3, the skin or water depth H, and the optical coupling factor K (the efficacy of the projection of the nanobubble image to the photodetector 307). Knanobubble can include the maximal diameter of the transient vapor nanobubble Dvnb, and the diameter of the focal spot in skin Ds of the working Lens L2. The optical coupling factor K can be further determined by the alignment of the focal spots of the working Lens L2 and the photodetector Lens L3, the ratio of the focal spot of the photodetector Lens L3 to the diameter of the photodetector 307, and optical losses inside the system including losses due to the optical aberrations. Larger diameters of the focal spots Ds can reduce the influence of the nanobubble factors on the collection of optical scattering by the transient vapor nanobubble.
Factors influencing the background level (base level) I of the background signal can be related to the probe beam illumination Killumination the collection Kcollection. Accordingly, one challenge of the optical detection systems disclosed herein can include reducing detection of the light scattered by skin and improving the relative sensitivity to detection of the light scattered by the transient vapor nanobubbles. Lower optical sensitivity to nanobubbles may be caused by poor optical delivery of the light from the transient vapor nanobubble to the photodetector in a high optical background created by the light delivered to the photodetector from the skin volume other than the transient vapor nanobubble. This may be caused by suboptimal optical properties of the working and the photodetector lenses L2 and L3, their suboptimal mutual alignment, and/or by too broad a probe beam spot at the transient vapor nanobubble plane.
The polarity of the optical scattering signal of a transient vapor nanobubble depends upon the position of the transient vapor nanobubble relative to the source of the scattered background light. A positive polarity is associated with the light collection focus between the transient vapor nanobubble and the lens L2 (or at the transient vapor nanobubble). As shown in
As shown in
In the case when the malaria sensor include a plurality of optical fibers without free-space optics, the distal tip of the optical fiber delivering the laser pump bean can be directed at the angle of about 30 degree to about 45 degree to the measurement site. A curved surface of the distal fiber tip can act as a focusing lens that concentrates the optical energy at specific depth in the skin. The focal distance of the fiber can be defined as the distance from the surface of the fiber tip to the depth where the fluence reaches the maximal level, compared to that from the laser beam that propagates from the standard fiber with a flat tip. Optimal depth of the energy concentration can be about 250 um to about 350 um as measured orthogonally to the skin surface. To achieve such focal length in water, the radius of the fiber tip can be in the range 50-70 um. For fibers with the core diameter of 200 um and higher, this is lower than the radius of the fiber and hence some tapering of the fiber tip may be required. The fiber diameter can be recessed to that of the doubled radius of the curvature. In case of the angled launch, the focal distance can be increased to match the actual angle.
The diameter of the laser pump beam at the skin surface can be about 130-200 um. Smaller beams may lead to higher background signal caused by optical absorption be melanin. The effective focused diameter of the beam (defined as the diameter where the pulse fluence is above the vapor nanobubble generation threshold, which can be approximately 20 mJ/cm2), can be about 50-60 um. Further increase of the beam diameter may result in the decreased laser fluence and thus fails to generate vapor nanobubbles.
The lensed optical fiber 401, 402, 403 can deliver a pump beam having a skin entrance diameter of about 150 um to about 300 um to a measurement site deep in the skin, such as to below skin surface. The skin entrance diameter of the pump beam can be chosen to reduce or minimize the melanin-generated background signal and/or false-positive signals. When focusing the pump beam into the skin, the focal spot of the pump beam can be at least 50 um in diameter (in the skin) and located at the skin depth of about 250 um to about 350 um. When focusing the pump beam into water, the focal spot of the pump beam can be at least 50 um in diameter and located at the depth of about 240 um to about 660 um below a surface of the water. Example data obtained using 10 different lensed fibers and a reference standard 105 um core diameter multi-mode step index fiber with a flat distal tip are summarized in Tables 2-4 (with Table 4 illustrating energy performance data of the sample tested lensed fibers when the input energy after the fiber collimator Lens L4 was 23.7 uJ) and the parameters are defined below:
A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
In some embodiments, a laser pulse (671-674 nm wavelength, about 200-370 ps pule duration (or about 240-300, or about 250 ps, or about 300 ps, or about 370 ps), energy 10-50 uJ) can be delivered via a single multi-mode optical fiber. The fiber can be step index and made of silica. For the pulse energy 20 uJ and higher, the core diameter of the optical fiber can be 105 um or 200 um, with a numerical aperture of 0.2, or 0.1-0.22, or similar. The fiber can have a cladding diameter of 125 um or 225 um. Such a configuration can reduce optical delivery loses in the fiber, the fluence at the level of melanin, and better concentrate the pump laser energy. The optical fiber can have front input/front output, or be side-firing (side input/side output). A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
At the proximal end of the optical fiber for delivery the laser pump beam, the fiber can be coupled to a FC/PC connector. The fiber tip can be positioned beyond the focus of the coupling lens in order to launch the divergent beam, which can maximally fill the fiber aperture so the beam diameter is about 0.7 time of the fiber core diameter. This solution can reduce the probability of the optical damage to the fiber due to the high optical intensity of the pump laser pulse. The optical damage threshold may be 3 GW/cm2 for a step index fiber. The total length of the fiber can be 12-14 m. Such a length provides better optical mixing of laser beam modes inside the fiber and thus reduces hot spots at the fiber output (see beam images in
The distal tip of the optical fiber can be flat or focused (lensed). The taper lens can have a radius of about 70-100 um. The focal distance of the lensed tip can be about 250-350 um. The optical fiber can be placed orthogonal to the skin or at an angle to match the volume of the probe beam delivery and/or collection fibers.
In some embodiments, the lensed fibers disclosed herein may be used both for the delivery of the pump and/or probe beams into the test sample, and for the detection of the scattered light. In this case, a single lensed fiber can act as a sensor for the Hemozoin-generated transient vapor nanobubbles. As will be described below, multiple optical fibers can be used for the delivery of the pump/and/or probe beams, and for the collection of the scattered probe beam.
In some embodiments, the probe light delivery fiber can include any suitable single mode fiber that delivers a continuous probe light (600-640 nm, or 700-100 nm, or 785 nm in wavelength, 20 mW or other optical power) with a low intensity noise. A single mode fiber can include a 4-8 um or 5-25 um mode field diameter, 125 um cladding diameter, and/or a standard numerical aperture. The proximal end of the single mode fiber can be coupled to a FC/PC connector or other connector. Standard laser coupling, including the mating sleeve, can be used. Total length of the fiber can be about 2 m, or between 1-12 m, or another length needed to connect the probe light source to the malaria sensor. The distal end of the probe light delivery fiber can include a flat tip. The distal end of the probe light fiber can have front input/front output, or be designed side-firing. The probe light can be launched into the skin or another measurement site at an angle (for example, at about 20-45 degrees) and location that delivers the probe light into the focal volume of the excitation or laser pump pulse and into the focal volume of the probe light collection fiber. The probe light delivery fiber can also be a multi-mode fiber with 10-25 um core diameter. The multi-mode fiber can be used with a multi-mode probe laser. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
In some embodiments, a probe light collection fiber (for collecting the scattered probe light) can include a multi-mode fiber. To collect more probe light from the skin surface, the fiber can have a core diameter of about 200-400 um, and/or higher NA (about 0.3-0.5 or higher). The fiber can have a cladding diameter of about 225 um or otherwise. The light collection performance of the fiber can be increased with a lensed tip. The fiber can be made of glass, a plastic, or another suitable material. The proximal end of the fiber can be coupled to a FC/PC or other connector. The fiber can include an in-line optical filter (for example, fibers made by Thorlabs with two insets) for improved suppression of the pump pulse wavelength. The proximal end can be operably connected to the photodetector (for example, the Menlo Systems 510 or similar for a maximal signal frequency of 20 or 50 MHz). Total length of the fiber can be about 2 m, or about 1-12 m, or another suitable length needed to connect the photodetector and optical filter to the sensor. The distal end of the probe collection fiber can include a flat or lensed tip with a maximal possible numerical aperture. If the tip includes a tapered lens with the radius of about 70-100 um, or a ball lens with a radius smaller than 200 um, the focal length can be about 300-700 um. The collection fiber can be applied to the skin or other measurement site orthogonally or at a zero angle. If a fiber with a flat standard tip is used, its axis can coincide with the volume of the focused pump pulse (that is, the volume where the vapor nanobubbles are generated) and with the illuminating probe light. If a lensed fiber is used, its focus can also coincide with the volume of vapor nanobubble generation. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
Preliminary Example Results of Using Optical Detection Systems Incorporating the Lenses
Example Simulated Results of Optically Detecting Particles Under the Skin
In
The optical detection process that was performed with the 25 um particles was repeated at four different skin locations with silver-coated micro-particles having an outer diameter of about 5 um. The difference between the micro-particle and the skin tissue is shown in
As illustrated in
Example Results of Optically Detecting Gold-Generated Transient Vapor Nanobubbles
When a transient vapor nanobubble is unrestricted (for example, when generated in water or other types of fluid), the expansion and collapse of the transient vapor nanobubble can be symmetrical.
However, in reality, the expansion and collapse of a transient vapor nanobubble, which may be in the patient's skin, may not be symmetrical due to the environment surrounding the vapor nanobubble.
As described above, the skin significantly attenuates the transient vapor nanobubble signal compared to that in water. After optimizing the alignment of the optical system as illustrated in
The statistical summary for the water and the skin for the two different settings of the probe beam (L1) collimator is shown below in Table 8. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
The optical system can be optimized for detecting transient vapor nanobubble in the skin in the following manner. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
Under the current settings, small nanobubbles of 100 ns lifetime (smaller than those detectible acoustically where the minimal detectible nanobubble had 300 ns lifetime, see U.S. application Ser. No. 16/213,923) can be detected with a relatively poor SNR of 3. To improve the SNR, spatial filtering of the probe beam can be applied between the photodetector and the photodetector lens (L3). In early experiments in which a single mode optical fiber was used as a spatial filter to deliver the probe beam to the photodetector (the details of which are described below), the noise of the background was about 10-20 fold lower while the signal amplitude was comparable to that shown in the table above. However, using the single mode fiber may not be efficient because the core diameter of the single mode fiber, which is about 9 um, may be too small to collect enough light. In some embodiments, the diameter of a spatial filter can be designed to match the diameter of the probed zone, which is corrected by the factor Fphotodetecto/Fworking. Accordingly, for a 20-um probed zone, the correction factor can be 2.6 (40 mm/15 mm). As a result, the diameter of the spatial filter would need to be close to a 50-um pinhole for the 20-um probed zone. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
Example Experimental Results of Using an Optical Detection Experimental Setup to Detect Malaria Parasite in Skin
Example Model with Single Mode Optical Fiber (9 Um Core Diameter) as a Spatial Filter
The malaria parasite excitation beam or pump beam can be delivered from above the model, through the glass slide 1114. The gold nanofilm 1112 does not absorb the pump laser pulse having a wavelength of 671 nm. Accordingly, no transient vapor nanobubble can be generated (see
Additional laser pulses having a wavelength of 532 nm was also delivered directly to the gold nanofilm 1112 from a bottom surface of the model, through the glass slide 1116. The gold nanoparticles can absorb the laser pulse at that wavelength. Accordingly, the gold excitation pulse (that is, having a wavelength of 532 nm) can generate a single vapor nanobubble at the surface of the gold particles (see photodetector signals shown in FIGS. 11D (intact skin) and 11E (skin with parasite), which illustrate the skin signal in response to a laser pulse with a wavelength of 532 nm and energy of 20 uJ from below the gold nanofilm 1112 through the air).
The optical excitation and detection were performed in a non-contact manner. The optical fibers for delivering the excitation (pump) laser pulses both terminate in the air and were not coupled to the test samples, including the glass slides 1114, 1116. The detection optics also terminated in the air and were not coupled to the test samples, including the glass slides 1114, 1116. The experimental setup as shown in
Further as shown in
As shown by
As shown above, the skin sample with the malaria parasites can deliver nanobubble-specific signals that are different for consecutive pump beam pulses. The signal can have an arch shape for the first laser pulse. The signal can show decaying of the amplitude and/or shape for the second and subsequent laser pulses.
In addition, vapor nanobubbles, photothermal effects (transient heating) and photoacoustic effects (pressure wave) all produce signals of different shape. The nanobubble signal shows the arch shape for the duration of the nanobubble lifetime (about 20 ns to about 2000 ns). The acoustic transient signal shows a bipolar spike for the duration of about 10 ns. The photothermal heating effect signal shows a step-like exponential signal for the duration greater than 1 microsecond.
An intact dark human skin sample of about 150 um in thickness does not produce any detectable signals when the focal volume was located at the depth of around 170 um. The signal observed at the photodetector may remain a flat line with the amplitude determined by the detector noise. A dark human skin sample of about 150 um in thickness with residual Plasmodium falciparum parasites at its bottom can produce all three types of the signals, including those due to Hemozoin-generated transient vapor nanobubbles.
Moreover, the optical scattering system such as shown in
The smallest detectable gold-generated transient vapor nanobubbles in a skin sample can be of 15-20 ns lifetime. This transient vapor nanobubble can be 20-fold smaller than the threshold of acoustic detection of transient vapor nanobubbles (which may be about 300 ns using a hydrophone as described in U.S. application Ser. No. 16/213,923, which may have a size of 0.4 mm). The smallest detectable parasite-generated nanobubbles in a skin sample can be of about 100 ns or less lifetime, with an SNR greater than 10. Compared to ultrasonic (that is, acoustic detection) data obtained for the same skin models in U.S. application Ser. No. 16/213,923, the optical detection systems disclosed herein may improve both the sensitivity and selectivity of the detection of parasites and also offer a possibility of non-contact detection.
The human skin can have a damping effect on the transient vapor nanobubble expansion and can also delay the transient vapor nanobubble collapse. The damping effects are not present in the transient vapor nanobubble signals generated under identical excitation conditions in water. Similar damping effects are also observed with acoustic detection of transient vapor nanobubbles.
In some embodiment, the current setup may be modified to include a coaxial and permanently aligned pump laser beam.
Example Optical Detection System Without Spatial Filter
As described above, the optical detection systems can also include no spatial filter (or optical fiber).
Transient vapor nanobubble detection under the skin was first verified using the positive control sample (that is, the black marker). Second, the negative control sample (that is, the intact skin) and the test sample (that is, skin with parasite) were tested under identical conditions.
Transient vapor nanobubble detection under the human skin was first verified using the positive control sample (that is, the gold particles). Testing the positive control sample can ensure that transient vapor nanobubbles, if generated, were detected. Second, the control sample (that is, the intact skin) and the test sample (that is, skin with parasites underneath) were test under identical conditions. The probe laser beam had a wavelength of 1310 nm.
An L1 collimator having a focal distance of 7 mm was used. When a weak transient vapor nanobubble signal was detected, the base level was adjusted to maximize the amplitude of the detected signals. In the results shown in
An L1 collimator having a focal distance of 14 mm was then used and the signals detected by the photodetector were collected at a Z position of 100 um. The detected signals and related data are shown in
The L1 collimator having a focal distance of 7 mm was reused and the base level was re-adjusted back to the maximum value of 300 mV.
As shown above, a total of six independent experiments in dark human skin with human malaria parasite models were performed with the example optical detection system without spatial filtering. In those experiments, the transient vapor nanobubble signals were observed mainly in the test sample (that is, dark human skin sample with malaria parasites underneath). That is, skin samples with the malaria parasites underneath delivered signals specific to transient vapor nanobubbles.
The polarity of Hemozoin-generated transient vapor nanobubble signals may often be negative, thus indicating that the transient vapor nanobubbles mainly form the signal by scattering the probe beam coming from some other source (such as the skin tissue) to the photodetector. The polarity of Hemozoin-generated transient vapor nanobubble signal also depends upon the relative position of the Hemozoin-generated transient vapor nanobubble and the optical focus of the collection system, as described above. When the Hemozoin-generated transient vapor nanobubble is between the optical focus and the working lens L2, the signal polarity would be negative.
Intact human skin samples may deliver some signals that appear to have characteristics specific to the transient vapor nanobubble. However, such signals were mainly observed when the focus of the excitation (pump) pulsed laser beam was lifted high enough so that melanin might have been present in the focused pump beam pathway. At a lower level of the Z position (closer to the bottom surface of the skin sample), there was a consistent significant difference in both the probability and the amplitude of nanobubble or nanobubble-like signals in intact and parasite skin samples studied.
The optical detection of transient vapor nanobubbles may require scanning the skin sample through about 60 locations or another number of locations, from 3 to 100 locations. Each of the locations is assumed not to have been previously exposed to the previous pump laser pulse(s). Compared to detecting the generation of transient vapor nanobubbles in water, detecting the generation of transient vapor nanobubbles in skin requires lifting the optical detection system in the Z position by about 50 um to about 100 um. This lift may indicate a shift of the optical collection focus in skin to a longer distance compared to that in water, for example, by about 50 um to about 100 um.
The diameter of the probe beam in the optical detection systems disclosed herein (as determined by the collimator L1 settings) may not noticeably influence the diagnostic performance of detecting the generation of transient vapor nanobubbles in skin. However, the sensitivity and/or selectivity of the optical detection system to detecting the transient vapor nanobubbles in skin can be improved if the probe beam is slightly shifted off-axis from the photodetector so that the background level is not at the maximum at the angle from which the probe beam is directed to the skin. This may indicate that a significant amount of background light comes from areas in the skin that are beyond or outside the boundary of the diagnostic volume. As described above, the background light outside the boundary of the diagnostic volume may be reduced and/or removed by using a spatial optical filter in front of the photodetector.
In some embodiments, the probe optical power required for the detection of Hemozoin-generated transient vapor nanobubbles in dark human skin at the depth of up to about 270 um can be in the range of about 5 mW to about 50 mW. The maximal size (that is, lifetime) of optically-detected transient vapor nanobubbles can be smaller than the size (that is, lifetime) of the acoustically-detected transient vapor nanobubbles in a similar model. In some embodiments, the optically-detected transient vapor nanobubbles can have a lifetime of about 0.1 us, whereas the acoustically-detected transient vapor nanobubbles can have a lifetime of about 0.8 us to about 1.0 us. Accordingly, the optical method may have a higher diagnostic sensitivity to that of the acoustic detection method of Hemozoin-generated transient vapor nanobubbles.
In some embodiments, the intensity noise of the probe beam source can be reduced to improve the diagnostic performance of the optical detection system. For example, an incoherent source, SLD, having a wavelength of 1310 nm and a noise level of 0.5% (peak-to-peak noise amplitude relative to the level of the background) may be replaced with the ultra-low noise laser, which may have much lower noise amplitude in the signal frequency range of about 50 kHz to about 20 MHz, which is the signal frequency range of interest. In some embodiments, additional frequency filters can be applied to the electric signal output of the photodetector. In some embodiments, an optical or electrical subtraction of the noise component can be used in the photodetector and/or in the signal processor. In some embodiments, a spatial filtering can be applied to reduce the background light without reducing the light backscattered by a transient vapor nanobubble.
Example Computational Modeling
Based on the performance of the optical detection system for detecting a transient vapor nanobubble in water, the data of which were measured experimentally, the performance of the optical detection system when used in on the human skin can be simulated. The measurements from experiments in water are summarized below in Table 10. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
Example simulation results are shown in
Optical Detection Using Example Micro-Fluidic Method and/or Device
As described herein, the optical detection systems disclosed herein not only can be employed on the human skin in situ, but can also be applied to a sample of the patient's body fluid (for example, blood, urine, or otherwise). In some embodiments, the body fluid can be contained in a micro-fluidic device configured to allow the flow of fluid to receive the pump and probe beams.
When performing diagnose and/or mass screen on patients potentially having malaria and/or other life-threatening diseases, the standard malaria diagnostics (such as microscopy and RDT) may be inconclusive so that it is not possible to confirm or exclude such subjects from malaria diagnosis and treatment. Although PCR has higher sensitivity than the standard malaria diagnostics, PCR is much more expensive, a more complex process, and also more time-consuming. At the same time, the clinical condition of many such patients can be quite severe so that the patients may have a higher risk of fatality if not treated timely for malaria, although their blood may have such a low level of malaria parasites that they cannot be reliably detected by the standard methods mentioned above. It is also not advisable to prescribe malaria medications for patients who do not have the malaria parasites due to the undesirable side effects of those medications. The optical detection of malaria parasite and/or Hemozoin using the micro-fluidic device can have a higher sensitivity and be quicker and more reliable than standard malaria diagnostics.
As shown in
In some embodiments, such as shown in
In some embodiments, the pump beam 1600 can include pump laser pulses with a duration of about 28 ps and a wavelength of about 672 nm. The pump beam 1600 can have a cross-sectional diameter of about 46 um. The pump beam 1600 can have a fluence of about 500 mJ/cm2. The probe beam 1602 can include a laser beam. In some embodiments, the probe laser beam can be continuous. In some embodiments, the probe laser beam can be pulsed. The probe laser beam can have a wavelength of about 632.8 nm or otherwise. In some embodiments, the probe laser beam can have an energy of about 1 mW. Alternatively, the probe beam can include an incoherent light emitted by an SLD. The probe beam 1602 can be focused into the center of the micro-cuvette 54. The diameter of the focal spot of the probe beam 1602 can be about 10 um. In some embodiments, the transmitted probe laser beam can be coupled into a single mode optical fiber, which is in turn connected to an amplified photodetector 1604. The optical fiber can have a mode field diameter of about 5 um.
The flow of fluid in the micro-cuvette can form a parabolic velocity profile which, coupled to the length of the micro-cuvette, can result in partial hydrodynamic focusing of the particles (including malaria parasites and Hemozoin) in the axis of the flow. This focusing effect can concentrate the generation of Hemozoin-generated transient vapor nanobubbles in the center of the flow that is exposed to the probe beam, which can improve the detection of malaria parasite and/or Hemozoin particles.
Several parameters of the optical detecting system using a micro-fluidic device were studied in example experiments with Hemozoin and malaria parasites, which were prepared from blood of malaria positive patients.
5,000 to 10,000 signals were obtained during the flow. In
Influence of Cuvette Size
The flow rate in the 0.1-mm ID micro-cuvette was set at 0.442 uL/min (with the measured flow rate being 0.385 uL/min). The flow rate in the 0.075-mm ID micro-cuvette was set at 0.249 uL/min (with the measured flow rate being 0.217 uL/min). The laser pump beam applied to the fluid flow in both micro-cuvettes had a pulse duration of 28 ps and a focal spot of about 46 nm. The laser pulse had a wavelength of 672 nm and a fluence of about 500 mJ/cm2.
As shown in
Influence of Centrifugation of the Blood Sample During Sample Preparation
The flow rate was set at 0.442 uL/min (with the measured flow rate being 0.385 uL/min) in both micro-cuvettes. The laser pump beam had a pulse duration of 28 ps and a focal spot of 46 nm. The laser pulse had a wavelength of 672 nm and a fluence of about 500 mJ/cm2. Both blood samples had about 8 parasites per uL. The blood sample that was centrifuged was centrifuged once at 14,000g for 10 minutes.
As shown in
Influence of Flow Rate
The flow rate was set at between about 9.442 uL/min to 0.442 uL/min (with the measured or real flow rate being less than the set flow rate by about 13%). The laser pump beam had a pulse duration of 28 ps and a focal spot of 46 nm. The laser pump pulse had a wavelength of 672 nm and a fluence of about 500 mJ/cm2. The blood samples had about 2 parasites per uL.
As shown in
Influence of Laser Pulse Parameters
The flow rate was set at about 0.442 uL/min (with the measured or real flow rate being about 0.385 uL/min). The laser pump beam had a pulse duration of 28 ps and a focal spot of 46 nm. The laser pulse had a wavelength of 672 nm. The fluence of the laser pulse was varied between about 200 mJ/cm2 to about 500 mJ/cm2. The laser beam was located at about 35 mm from the beginning of the micro-cuvette.
Three test samples were prepared. The first sample included water. The second sample included water with polystyrene nanoparticles having an outer diameter of about 1 um. The third sample included a solution of Hemozoin at a concentration of about 9.97 pg/uL, which was equivalent to approximately 17 parasites per uL. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
As shown in
Studies have also been conducted to establish the basis for optimizing the Hemozoin detection in the micro-fluidic device for Hemozoin nanoparticles at a lower concertation. In those studies, the malaria-specific laser pump pulse had a wavelength of 671 nm and a fluence of 500 mJ/cm2. Three samples were prepared. The first sample included water. The second sample included a solution of Hemozoin isolated from a Plasmodium falciparum culture having a parasite concentration equivalent to about 2 parasites per uL. The third sample included a solution of Hemozoin isolated from a Plasmodium falciparum culture having a parasite concentration equivalent to about 0.2 parasites per uL. Hemozoin is purified from the whole blood using standard published methods.
As described above in
The capillary tube 1954 can include optical flange windows 1958, 1960 on or near opposite ends of the tube 1954 along its length. The capillary tube 1954 can act as an optical light guide, similar to that of an optical fiber. The optical flange windows 1958, 1960 can allow a passageway for the beams 1900, 1920 along the length of the capillary tube 1954. The pump and probe beams 1900, 1902 can propagate inside the flow 1955 along a length (or a portion thereof) of the capillary tube 1954 and fill or substantially fill the whole cross-section of the capillary tube 1954. The beams 1900, 1902 can propagate due to internal reflection from the inner capillary wall. The refractive index of the capillary tube 1954, which may be made of glass or polymer, can higher than that of the liquid sample. The propagation can be at such low angles of incidence that both beams 1900, 1902 may propagate in the flow 1955 for some distance before leaving the capillary tube 1954, for example, via the flange window 1960. As shown in
This collinear flow-beam arrangement if
In some embodiments, the micro-fluidic device 1950 as shown in
In some embodiments, installing filters of a specific size along or at the output of the flow of a liquid sample from a light guide, such as an optical fiber or the capillary tube 1954 described above, may allow further concentration of parasites and/or Hemozoin inside the light guide or at the output of the light guide. If the pump and/or probe laser beams enter the light guide in the direction opposite to that of the liquid flow (such as shown in
In
Example Statistical Analysis for Optically Detecting Malaria
In some embodiments, the optical detection data can be analyzed statistically to provide additional confirmation that malaria parasite and/or Hemozoin has been detected. The statistical analysis can follow the steps in
The concept of the signal decay will be described using results from an experimental model. In this model, a layer of dermis tissue (about 750 um thick) was covered by a layer of dark skin (about 250 um thick) so that a total thickness of the sample about 1 mm. A Plasmodium falciparum parasites suspension was applied to the top of the dermis layer and incubated for about 15 minutes before the dermis layer with parasites was covered by the skin layer so that the parasites are between the dermis and the dark skin to create a test sample.
One of the optical detection systems disclosed herein was applied to the test sample. The pump laser beam had a wavelength of 671 nm and an energy of 17 uJ. The pump beam had a focal point at 380 um (in water). The pump beam had a cross-sectional diameter of about 120 um at the surface of the test sample and a cross-sectional diameter of about 150 um at a depth of about 250 um, that is, at the depth of the malaria parasites in the test sample. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
Signal acquisition was performed according to the following steps shown in
The diagrams shown in
As described above, compared to intact skin, Hemozoin-generated transient vapor nanobubble signals can demonstrate apparent decay, that is, the decrease (often to zero) in the signal amplitude in response to consecutive laser pulses applied to the same location. However, many large Hemozoin-generated transient vapor nanobubbles can still return non-zero signals during consecutive laser pulses because of the large amount of Hemozoin involved. The greater the concentration of Hemozoin in the parasite, the longer or more laser pulses it takes to destroy such Hemozoin nanoparticles. As a result, the decay value can be analyzed as the ratio of signal amplitudes for the first verses the third and/or fourth laser pulses applied to the same location.
With continued reference to
A value pair of amplitude of the first signal A and the decay value D can be obtained, such as shown in
At step 2034, the processor or controller in communication with the photodetector can measure an amplitude A1 (see
At step 2036, the processor or controller can measure an amplitude A2 (see
At step 2038, the processor or controller can calculate the decay value D as a ratio of A1 to A2. At step 2040, the processor or controller can save A1 and D values for each position of the test sample, for example, on a memory device in communication with the processor or controller. In some embodiments, the processor or controller can form a table of N pairs of A and D, available for graphical presentation and/or for the calculation of the statistical analysis.
The A1-D pairs can be used to make a malaria-positive diagnosis, such as using the diagnostic algorithm shown in
At step 2044, the processor or controller can analyze the A1-D distribution for malaria-positive samples to determine the relative change in metrics values and the relative level (which can be expressed as a probability P) of the malaria-positive signals whose metrics exceed the preliminary threshold determined in step 2042. In some embodiments, the probability P can be calculated as:
N(signals above the preliminary threshold)/N(total number of signals).
At step 2046, the processor or controller can determine an amplitude threshold Ath and an decay threshold Dth only for the malaria-free and malaria-positive signals that exceed the preliminary threshold determined in step 2042. At step 2048, the processor or controller can compare the values of P, Ath, and Dth for the malaria-free and malaria-positive signals. At step 2050, the processor or controller can determine the malaria positive values based on the comparison in step 2048. In some embodiments, the preliminary thresholds and/or malaria positive values can be determined manually. In some embodiments, the preliminary threshold and/or malaria positive values can be determined using a mathematical model and/or neural network model trained to perform the statistical analysis on the optically detected signal.
As described above, the polarity of the Hemozoin-generated transient vapor nanobubble signal may be both negative and positive depending upon the vertical position of the vapor nanobubble. “Upper” vapor nanobubbles (those formed in the upper skin layer) scatter the light “returning” from backscattering by the skin. Therefore, those nanobubble signals produce a negative signal. “Lower” vapor nanobubbles (those formed in the lower skin layers) scatter the incident probe light. Therefore, those signals produce a positive signal. Multiple Hemozoin-generated transient vapor nanobubbles may create one or several different signals in response to a single pump laser pulse.
In one experiment using the experimental model described above, no significant time-shift was observed for all Hemozoin- or malaria-positive signals. All the Hemozoin-generated transient vapor nanobubble spikes began at about 100 ns to about 200 ns time-point.
In some embodiments, the malaria sensor can include an array of optical fiber bundles (which are described in greater detail below), with each bundle capable of detecting malaria optically in one location of the measurement site.
Distortion of Optically Detected Transient Vapor Nanobubble Signals
In some embodiments, not all the transient vapor nanobubble signals that are detected by the photodetector exhibit a dip-shape, such as shown by the yellow dash line 2506 in
A gold particles in water experimental model was used to study the effects of two cases of a lateral shift of a transient vapor nanobubble relative to the aperture of the probe beam when the probe beam diameter was about 20 um, the energy level of the pump beam, and the relative sizes of the pump beam and the probe beam.
In the first case, a single transient vapor nanobubble in one specified location was generated with a pump laser pulse having a wavelength of 532 nm. In this case, the lateral position of the probe beam was varied by moving the optical system relative to the location of the single transient vapor nanobubble.
For the signals in
For the signal in
As shown in
In the second case, one large transient vapor nanobubble or many transient vapor nanobubbles were generated within an aperture of the pump beam that is about 2-3 fold larger than the aperture of the probe beam. The pump laser pulse had a broad pump beam having a diameter of about 30 um to about 40 um. The area of transient vapor nanobubble generation was larger than the aperture of the probe beam. This situation was similar to the Hemozoin-generated transient vapor nanobubble excitation and detection in situ at a patient's skin. The lateral position of the probe beam remained the same in the second case since the pump pulse was delivered through the same optical system as a probe beam. The pump beam was a laser pulse having a wavelength of 671 nm pulse.
Signals observed in
The maximum amount of lateral shift of the probe beam may be limited to about 10 um or about 50% of the probe beam aperture before the transient vapor nanobubble signal becomes undetectable. Regardless how much the lateral shift of the probe beam is (within the maximum amount of shift) and/or how much larger the excitation area of the pump beam is, time-shifts of transient vapor signals may not be significant. The maximal time-shifts in the first and second cases disclosed herein did not exceed about 100 ns for the detectable transient vapor nanobubble signals.
The distortion effect of the parasite concentration on the transient vapor nanobubble signal was also studied using malaria-free and malaria-positive skin samples. This experiment used three malaria-positive skin samples, each 1 mm in thickness. The first sample was an intact malaria-negative skin sample. The second and third samples each included parasites in the depth range of between about 230 um to about 500 um under the skin surface. One of the malaria-positive samples, the second sample, included a skin sample with a typical concentration of parasites for a malaria patient. The second one of the malaria-positive samples, the third sample, included a skin sample with residual parasites (that is, parasites were added to an intact skin sample in a very low concentration, such as being 1-2 orders of magnitude lower than the parasite concentration in the second sample). Laser pulses of an energy level of about 15 uJ were applied to all three samples. Four pulses were applied to each location, for 20 different locations in each sample. The probe beam had a diameter of about 120 um at the skin surface or entrance. The probe beam had a focal depth of about 370 um in water. At the laser pulse energy level of about 15 uJ and when coupled with a focused probe beam geometry, relatively larger Hemozoin-generated transient vapor nanobubbles were generated around the malaria parasites in the second and third skin samples.
In
To make the signals more representative of the transient vapor nanobubbles and their relative sizes, the optical collection and detection paths can be optimized so that signals of the largest transient vapor nanobubbles have the highest amplitude and do not reverse into signals with low amplitude and/or an irregular shape. The settings of the collection optical path of the system can be modified to widen the dynamic range with the highest sensitivity for the small transient vapor nanobubbles generated in the center of the probe beam. The collection and the scattered light can also optionally be improved in other embodiments to better detect transient vapor nanobubbles generated further from the center of the probe beam and/or to have a higher dynamic range to correctly report any large transient vapor nanobubbles.
In addition, the A-D diagram described above can be used to further improve the accuracy of the optical detection of the transient vapor nanobubbles. The A-D diagram can be in the form of a signal amplitude-based A and D or a signal area-based A and D. A transient vapor nanobubble optical scattering signal can increase in its amplitude and duration with an increase in the diameter of the transient vapor nanobubble. As a result, the area of the signal (which can be calculated as the amplitude integrated over the duration of the transient vapor nanobubble component of the signal) may be more representative of an indicator than its amplitude in indicating the size and/or lifetime of the transient vapor nanobubble, especially when the amplitude may have been compromised (reduced and/or distorted) by suboptimal optical collection of the nanobubble-scattered light.
The sample-averaged metrics, including the transient vapor nanobubble probability P, the signal amplitude or area A, and the signal decay value D were also obtained and compared for the amplitude- and area-based methods, as shown in
As shown in
As shown in Table 11 and
As suggested by
In some embodiments, the area calculation algorithm can use the following steps to remove the background component. The processor or controller coupled to or in communication with the photodetector can determine the baseline level by calculating the average of the part of the signal with negative time (that is, pre-trigger signal). The processor or controller can apply the baseline and the threshold (such as determined by the circle in
In some embodiments, sample metrics, HI and N (as described in U.S. application Ser. No. 16/213,923), can be applied for the statistical description of P (as N), A amplitude, and A area, in which the metric HI can be the amplitude thresholds, and the decay can be the modified HI. The use of HI and N can result in up to about three or five (if amplitude and area both are analyzed) metrics per sample. Data for malaria-negative samples can be used to determine the diagnostic thresholds for each of these metrics.
Example Optical Detection Systems with Optical Fibers
In some embodiments, instead of a system of free-space optics, such as the lenses described above, an optical malaria detection system can include two optical fibers to deliver the probe laser beam to a transient vapor nanobubble (Hemozoin-generated transient vapor nanobubble in the case of the malaria detection), and to collect the light scattered by the nanobubble. An example system is illustrated schematically in
As shown in
The skin sample 10 can be placed on top of a gold nanoparticle film 12. The gold nanoparticle film 12 can be deposited on a microscope slide glass. The gold nanoparticle film 12 can be covered with the skin sample 10 as shown in
The pump laser pulse 2900 can also be delivered by an optical fiber, such as a lensed optical fiber. The pump laser pulse 2900 can generate transient vapor nanobubbles 20 in gold nano-film. The skin-gold model can simulate the malaria parasites and/or Hemozoin in the skin tissue of a patient and the transient vapor nanobubble 20 can simulate the Hemozoin-generated transient vapor nanobubble. The transient vapor nanobubble 20 can scatter the probe beam delivered via the first optical fiber 2903. The scattered probe light can travel along the second optical fiber 2905 and be detected by the photodetector 2904.
The first optical fiber, also known as the delivery fiber, can be a single-mode optical fiber. The delivery fiber can have a core diameter of about 5 um. The delivery fiber can have an outer diameter of about 125 um. The delivery fiber can have a numerical aperture of about 0.13. In some embodiments, the first optical fiber can be a pigtailed single mode fiber. In some embodiments, the delivery fiber can have a standard tip. In some embodiments, the delivery fiber can have a lensed tip. The delivery fiber can have a length of about 1 m. The delivery fiber can be coupled to the probe beam laser via a connecting sleeve (such as the sleeve 2901 shown in
The delivery fiber can be secured by a fiber holder with micro-positioning screws. The screws can allow adjustment of angles and positions in the X, Y, and Z directions. A micrometer indicator can be included to indicate the height of the fiber holder.
The photodetector can be connected to the second optical fiber, which can be a multi-mode fiber. The second optical fiber is also known as the collecting fiber. The collecting fiber can include a fiber optical filter (similar to the filter 2907 in
As shown in
As shown in
Transient vapor nanobubbles (for example, having a lifetime between about 100 ns and about 500 ns) can be detected in the dark human skin sample with the optical scattering method with two standard optical fibers that deliver and collect the probe laser beam. As shown in
As also shown in
Comparing the signal amplitudes in water (60 mV to 200 mV for a vapor nanobubble having a lifetime of about 300 ns to about 500 ns) and skin (2 mV to 5 mV for a vapor nanobubble having a lifetime of about 100 ns to about 300 ns) under the same energy level of the pump laser pulse, there can be a 40-60 fold decrease of the signal amplitude in the skin sample compared to the water sample. This ratio matches a similar water/skin ratio observed for similar signals described above with the free-space optical detection system.
In the experiment with the dark human skin sample, standard fibers with flat tips can be sufficient to detect a small transient vapor nanobubble (for example, having a lifetime of about 200 nm to about 500 ns) under the skin. In some embodiments, the optical detection system can be further improved to result in an increased sensitivity to the transient vapor nanobubbles. The improved optical detection system can also include bundling of the optical fibers into a single fiber bundle optimized for the delivery and collection of the probe light to and/or from the human skin.
A malaria sensor including an optical detection system may be designed as a combination of two or three bundled optical fibers to deliver the pump pulse and probe light and to collect the scattered probe light. To probe multiple locations, the malaria sensor can be designed as a matrix of multiple bundles united into a single sensor. A single bundle sensor can mechanically scan across the skin to probe multiple close locations of the skin. The pump and probe laser beams can be sequentially launched into each bundle to probe each location sequentially.
In some embodiments, the delivery and collection fibers can be united into a bundle with a common distal tip and separate proximal ends. Each of the proximal ends can be coupled to a FC/PC connector. The common distal tip can provide the delivery of the probe beam (which may have a wavelength of about 785 nm) along the axis of the collection fiber at a depth of 250 um into a test sample. For example, when the common distal tip was inserted into water, the probe beam can be delivered along the axis of the collection fiber at a depth of about 250 as measured from the tip of the bundle into the water. The point at the depth of 250 um is defined as the focal point. The common distal tip can also improve and/or maximize the optical collection of the light scattered at the focal point. The collection fiber can have a numerical aperture such as 0.5 or higher. A skilled artisan can appreciate based on the present disclosure that alternative parameters can be used in additional embodiments.
The delivery fiber of the probe beam may be a single-mode fiber. The output beam from the delivery fiber, that is, the probe beam, can have the aperture 20 um or less (which the single-mode fiber is suitable for). The surface of the tip of the fiber bundle can be angled in the way so as to direct the probe beam to the focal point. This corresponds to angles of between about 30 degree and about 50 degrees. The angle can depend upon the outer diameters of the delivery and/or collection fibers. The distal tip surface of the fiber bundle can be smooth and without any sharp parts.
As shown in
As shown in the distal end views in
The collection fiber 3505, 3605 can have a high numerical aperture (such as 0.5 or more). As shown in the top drawings of
As shown in
An optical fiber sensor for detecting malaria can include the horizontal fibers described herein. The fiber sensor can be applied parallel to the human skin. The optical fiber sensor can serve at least three functions. The optical fiber sensor can deliver a pump laser pulse. The optical fiber sensor can deliver a probe beam, for example, a continuous wave beam. The optical fiber can also collect the scattered probe light.
The sensor may optionally include three optical fibers assembled into a single bundle or a matrix of such bundles. In embodiments of the sensor having three fibers, such as shown schematically in
The sensor may include two fibers, such as shown schematically in
In some embodiments, the sensor may include the combination of optical fibers and ultrasound detectors, assembled to detect same HVNBs. The combination can further improve the sensitivity of detection of malaria parasites and/or Hemozoin in the patient.
The fibers in the optical fiber sensor can have flat tips. The flat tips may not be able to focus or collimate the light, and therefore may have a lower energy efficacy and/or lower detection sensitivity than fibers with lensed or convex tips. The lensed fiber or fibers with the engineered tips for delivering the pump beam and collecting the scattered probe light can better concentrate the pump fluence into the skin, and/or collect more scattered light from the skin compared to identical fibers with flat tips. Therefore, the lensed tips can increase the energy efficacy of Hemozoin-generated transient vapor nanobubble generation and/or the sensitivity of detection thereof.
In some embodiments, the fibers in an optical fiber sensor can be assembled at the relative angles to each other in order to achieve the desired angle of the delivery. The desired angle of delivery can affect the location or depth of the focal point in water or skin.
Example Detection Systems with a Fiber Mating Device
In some embodiments, an optical and/or acoustic malaria detection system disclosed herein can include a fiber mating device (rather than a standard fiber mating sleeve or just an optical fiber coupler) to further improve the malaria detection sensitivity threshold and/or consistency (that is, the diagnostic performance), for example, by reducing false positive detection in malaria-negative samples. Example methods, mechanisms, and designs for further improving the delivery of the laser pulse to the human skin through the effect of the self-collimation of the laser pulse in the optical fiber will be described below, in particular with reference to a unique way of delivering the pump laser pulse in a malaria detection system using the fiber mating device. In these embodiments, the fiber mating device can optically decouple a permanently-installed fiber (a service fiber in the sensor, which is described in more detail below) from the laser source using an additional optical fiber (a delivery fiber). The delivery fiber may be longer than the service fiber. The fiber mating device can include free space optics and mechanics with spatially disconnected fiber tips.
The self-collimation of the laser pulse in an optical fiber will now be explained. Typically the fiber numerical aperture, NA, of optical fiber determines the NA of an out-of-fiber light beam. However, the combination of the properties of a short high energy laser pulse (used for malaria detection and/or diagnostics as described herein) with specific coupling (launching) of such pulses, for example, using the fiber mating device described herein, into a multimode optical fiber can result in unique propagation of the laser pulse in the optical fiber, with the divergence (numerical aperture, NA) of the out-of-fiber laser beam being self-controlled by a laser pulse rather than by the numerical aperture of the optical fiber. This is because the NA of the laser beam at the fiber input is much smaller than that of the optical fiber. The pulsed laser beam self-collimates in the fiber, thus improving the delivery of the optical energy into the skin and hence the diagnostic performance of the optical malaria detection system described herein.
The actual NA of the out-of-fiber laser beams under different source-fiber settings were compared. Light sources with different pulse durations were used, namely 247 ps, 300 ps, and 370 ps. Optical fibers (Thorlabs Inc) according to the parameters described above were used. The optical fiber length and NA were varied, with all other parameters kept the same: for example, with a core diameter of 105 um, a step index (SI) multi-mode (MM) design, and having FC/PC standard connectors on both sides. Optical fiber tips were checked to be clean and to have no damage. Different optical fiber couplers and coupling lenses were used. Laser Source 1 and Source 2 were not coupled to a fiber mating device (which will be described in greater detail below). Laser Source 3 was coupled to the fiber mating device described above (which will be described in greater detail below), which could filter out unintended wavelengths (for example, wavelengths not according to design specification) and more optimally connect various fibers, as described above. For each coupling device and fiber, the lateral position of the fiber tip was adjusted for the maximum of the output laser energy.
For the NA measurement, the beam profile was measured with an Ophir SP928 system, which has been calibrated to measure an absolute NA of the beam, by using a fiber test optical source LE-1R-CE for multi-mode fibers (660 nm, LED non-coherent device, WWT Inc), which delivered the beam NA equal to that of the fiber (see
The NA of the laser beam out of the SI MM optical fibers was found to be significantly lower (for example, about 0.06-0.07) than the NA of the fiber (about 0.1-0.22). As a result, the beam out of the fiber was collimated much better (up to about 3-fold) than what the fiber provides.
The effect of the NA of the optical fiber for malaria diagnostics through Hemozoin-generated vapor nanobubbles will now be described. The generation and detection of Hemozoin-generated vapor nanobubbles in human skin was studied in 9 independent experiments with dark human skin with or without Hemozoin nanoparticles. The pump laser beam was directed to the depth of 250 um under the human skin. The NA of the optical fiber used for the delivery of the laser pulse into the skin was varied between 0.1 and 0.22. The combination of a light Source 1 (see Table 12 above) and a 12-m standard optical fibers was used. The energy of the laser pulse was maintained at the maximal possible level in the range of 18-20 uJ (at the skin entrance). Hemozoin-generated vapor nanobubbles were detected with an ultrasound sensor (Blatek Inc, model 0919-5782). Ultrasound signals were analyzed with two metrics, one related to the skin background (peak-to-peak parameter) and another related to the Hemozoin-generated vapor nanobubble (an “S2” parameter) in the signal tail, both as a function of the Hemozoin status and the optical fiber NA. An example of two experiments is shown in
Among the nine experiments performed, 5 experiments used an optical fiber with the NA 0.1 and 4 experiments used an optical fiber with the NA 0.22. Signal metrics were averaged for each of 9 experiments as presented below in the Table 13 and the S2-p-t-p diagram (
As shown in Table 13 and
The effect of the laser beam self-collimation has resulted in the actual laser beam divergence (NA) out of the fiber remaining in the close range of 0.06-0.075, regardless several design parameters, including but not limited to: the optical fiber NA (0.1, 0.22) and/or the length (2 m and 12 m); the laser pulse source (the three different lasers resulted in the same output NA of the beam as shown in Table 12 above); the optical fiber coupling device and its settings (three different couplers (including a fiber mating device) with the focal length of aspheric coupling lenses being in the range of 11-15 mm, resulting in the same output NA of the beam; the variation of the axial position of the lens (within 100 um) and of the lateral position of the input fiber tip (within 20 um, X and Y)); out-of-fiber energy of the laser pulse (for the energy range of 5.1-22.2 uJ, the NA of the out-of-fiber beam remained the same, within the measurement error range of 0.005, with the minimum being 0.063 and the maximum being 0.07 (measured for a 12-m long 0.22 NA fiber with the laser Source 2)).
The data obtained indicates that the effect of a self-collimation of the laser pulse in an optical fiber can be mainly determined by the properties of the laser pulse which are common for all three lasers: the wavelength, pulse duration range, and the coupling of the laser beam into the fiber. The coupling described herein can use the divergent beam after its waist, a relatively large beam diameter at the entry into the fiber core, which is slightly less than the diameter of the fiber core. The NA of the free-space laser beam in the coupler can be close to the observed NA values in Table 12.
The physical mechanisms behind the observed self-collimation of the laser beam may be explained through additional results observed. There was no additional loss of the optical transmission in the fibers (the energy transmission efficacy for the 12-m fibers was 85% and above). The pulse duration did not increase, and even slightly decreased, by about 2-3%, as was observed for the 12-m fibers versus the 2-m fibers (from 247 ns to 241 ns, as shown in test data for Source 3 in Table 12 above). The temporal structure of the laser beam changed from a single mode (at the fiber input) to a multi-mode (at the fiber output). These factors, together with the main result described herein, may indicate two mechanisms. The first mechanism involved non-linear optical effects self-induced by a laser pulse in the fiber due to high optical intensities (such as in the GW/cm2 range), which could occur during the pulse propagation through the fiber core. Such non-linear effects (for example, a weak Kerr effect) may create reversible changes in the optical fiber that, in turn, could focus the laser beam and slightly shorten the pulse duration, without damaging the optical fiber. In the second mechanism, the fiber input coupling of the free space laser beam with low NA (0.05) may help to maintain a low NA for the laser beam during its propagation through a multi-mode optical fiber.
The possibility of using this effect of self-collimation for a simpler, more reproducible, and more efficient control of the delivery of the optical energy into the skin and by using standard optical fibers is illustrated below for four different optical fibers. The out-of-fiber laser beams were imaged with the beam profiler for the combination of the light Source 3, a 12-m delivery fiber, and the fiber mating device (such as describe in more detail below) as shown in Table 14. The fiber mating device functioned as an intermediate optical filter, an attenuator, and a coupler. As shown in Table 14, all four different optical fibers delivered a relatively smooth beam (that is, without hot spots) of the NAs, similar to the results as shown in Table 12 above. In the beam profiles of
In the embodiments using the fiber mating device, the fluence of the laser pulse as delivered to skin at the depth of the vapor nanobubble generation (and hence the vapor nanobubble generation efficacy and consequently the diagnostic performance) can be increased approximately 2.5-fold higher than that when using a standard sleeve for connecting the laser source and the sensor through the direct connection of two optical fibers.
As described above, with a fiber mating device disclosed herein, the malaria diagnostic performance can be further optimized. For a range of optical fiber NA from about 0.1 to 0.22, the numerical aperture (NA) of the optical fiber may not influence the efficacy of Hemozoin-generated vapor nanobubble detection in human skin when the fiber mating device is used. Furthermore, the diagnostic performance may be higher than if assuming the out-of-fiber laser beam divergence follows the fiber NA. The improved collimation of the out-of-fiber laser beam can result in higher laser fluence in skin at the depth of generation of Hemozoin-generated vapor nanobubbles. Laser pulse mode mixing in optical fibers, as used for malaria detection sensors with a high energy picosecond laser pulse, can therefore be further improved to avoid one or more of the following issues: (1) uncontrollable divergence (and hence fluence variation) of the laser pulse in skin, (2) hot spots at the skin surface, (3) damage to the receiving end of the optical fiber resulting in a loss of the sensor as the fiber is permanently imbedded into the sensor, or (4) difficulty to maintain specific pulse energy in cases where the laser source has no attenuator. Any of these factors may compromise diagnostic performance. The fiber mating device can also address additional technical problems, including but not limited to (5) a parasite laser wavelength of about 808 nm, also present out of the optical fiber in case it is unfiltered in the laser, or (6) laser damage to the fiber tips when using two optical fibers mated in a standard sleeve (such mating also may not improve the laser beam profile since it simply extends one fiber into the second one and may not allow for control of the laser energy and/or wavelength). In other words, the fiber coupling using the fiber mating device between the laser source and the malaria detection sensor can facilitate in achieving improved and more reproducible diagnostic performance than the use of a standard sleeve for connecting two optical fibers.
In some embodiments, an optical and/or malaria detection system can perform a self-collimated delivery of the laser pulse with a standard optical fiber. The system can achieve a laser beam NA at the skin entrance in the range of about 0.05 to 0.07.
Using a fiber coupler 4202, the laser source 4200 can be coupled into a delivery fiber 4204. The delivery fiber 4204 can be a multi-mode fiber. In some embodiments, the delivery fiber 4204 can include a standard multi-mode step index optical fiber with a core diameter of about 50-200 um (for example, about 105 um), a length of about 2-20 m length (for example, about 12 m), and/or an NA of about 0.1-0.22 (for example, about 0.22). The fiber coupler 4202 can include aspheric lens (or other type lens), which may have a focal distance of about 7-18 mm (for example, about 11 mm). The laser beam at the entrance of the delivery fiber 4204 can be divergent, with the NA of about 0.0-0.1 (for example, about 0.05). The beam diameter at the tip of the delivery fiber 4204, which can be adjustable in a lateral directions, should be about 60-80% of the core diameter of the delivery fiber 4204.
The fiber mating device 4206, couples the delivery fiber 4204 with a sensor fiber (service fiber) 4210, which ultimately couples the laser source 4200 and the malaria sensor 4210. The fiber mating device 4206 can include an adjustable fiber mating free-space unit. The unit can include an optical filter and attenuator to control the laser beam energy and/or the divergence of the beam at the skin. As shown in
The service fiber 4208 can be a permanent and/or integral part of a non-invasive malaria sensor 4210 (for example, any malaria sensor examples including the photodetector as described above). For example, the service fiber 4208 can be permanently and/or integrally coupled to the sensor 4210. In some embodiments, the service fiber 4208 can include a standard multi-mode, step index optical fiber. The service fiber 4208 can have a core diameter of about 105 um (which can also be any value from about 50 um to about 200 um), a length of about 2 m (which can also be any value from about 1 m to about 10 m), and/or a NA of about 0.22 (which can also be any value from about 0.1 to about 0.4).
Additional example specifications of the components in the malaria detection system of
Splitting the delivery of the laser pulse into two optical fibers (delivery and service fibers), such as when connected via the fiber mating device, allows improvement of the laser beam intensity profile at the skin entrance so as to avoid or minimize hot spots in skin, among other technical problems described above when using a standard sleeve or a single optical fiber, and allows quicker replacement of the malaria sensors. In a modular design, the laser source, the fiber coupler, the delivery fiber, and the fiber mating device can be mounted as a whole and represent one unit, while a sensor with the service fiber can represent a separate unit.
The use of the fiber mating device can result in one or more of the following features: (1) improving stability of the intensity profile of the laser beam out of the malaria sensor: the spatial modulation (hot spots) could be reduced from about 80% (after an about 12-m fiber, see for example,
In addition, utilizing the self-collimating effect of the laser beams can allow use of an optical fiber with a standard flat tip to be used to achieve similar target depth pump laser fluence, similar to use of an optical fiber with a specialized engineered tip, which may be lensed (having a curvature) and/or include a taper.
Terms of orientation used herein, such as “proximal,” “distal,” “radial,” “central,” “longitudinal,” and “end” are used in the context of the illustrated embodiment. However, the present disclosure should not be limited to the illustrated orientation. Indeed, other orientations are possible and are within the scope of this disclosure. Terms relating to circular shapes as used herein, such as diameter or radius, should be understood not to require perfect circular structures, but rather should be applied to any suitable structure with a cross-sectional region that can be measured from side-to-side. Terms relating to shapes generally, such as “circular” or “spherical” or “semi-circular” or “hemisphere” or any related or similar terms, are not required to conform strictly to the mathematical definitions of circles or spheres or other structures, but can encompass structures that are reasonably close approximations.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
The terms “approximately,” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, in some embodiments, as the context may permit, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than or equal to 10% of the stated amount. The term “generally” as used herein represents a value, amount, or characteristic that predominantly includes or tends toward a particular value, amount, or characteristic. As an example, in certain embodiments, as the context may permit, the term “generally parallel” can refer to something that departs from exactly parallel by less than or equal to 15 degrees.
While a number of variations of the disclosure have been shown and described in detail, other modifications, which are within the scope of this disclosure, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the disclosure. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed.
Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a subcombination or variation of a subcombination.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings) may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination so disclosed.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Some embodiments have been described in connection with the accompanying drawings. The figures are not drawn to scale where appropriate, but such scale should not be limiting, since dimensions and proportions other than what are shown are contemplated and are within the scope of the disclosed invention. Distances, angles, etc. are merely illustrative and do not necessarily bear an exact relationship to actual dimensions and layout of the devices illustrated. Components can be added, removed, and/or rearranged. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with various embodiments can be used in all other embodiments set forth herein. Additionally, any methods described herein may be practiced using any device suitable for performing the recited steps.
Although this invention has been disclosed in the context of certain embodiments and examples, the scope of this disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Any system, method, and device described in this application can include any combination of the preceding features described in this and other paragraphs, among other features and combinations described herein, including features and combinations described in subsequent paragraphs. While several variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57. The present application is a continuation of U.S. application Ser. No. 16/992,596, filed Aug. 13, 2020, which claims priority benefit under 35 U.S.C. § 119 (e) to U.S. Provisional Application No. 62/888,060, filed Aug. 16, 2019, which is hereby incorporated by reference in its entirety herein. This application is also related to U.S. application Ser. No. 16/213,923, filed Dec. 7, 2018 and titled “APPARATUS FOR DIAGNOSING AND/OR TREATING MALARIA,” and U.S. application Ser. No. 16/829,609, filed Mar. 25, 2020 and title “MINIMALLY INVASIVE MALARIA SENSOR WITH MICRONEEDLE OR OPTICAL CAP,” the entirety of each of which are incorporated by reference herein and are part of this disclosure. Many of the embodiments described below are compatible with and can be part of the embodiments described in these related applications. Moreover, some or all of the features described herein can be used or otherwise combined together or with any of the features described in the related applications listed above.
| Number | Name | Date | Kind |
|---|---|---|---|
| 174504 | Chenausky | Nov 1979 | A |
| 4818710 | Sutherland | Apr 1989 | A |
| 4960128 | Gordon et al. | Oct 1990 | A |
| 4964408 | Hink et al. | Oct 1990 | A |
| 5319355 | Russek | Jun 1994 | A |
| 5337744 | Branigan | Aug 1994 | A |
| 5341805 | Stavridi et al. | Aug 1994 | A |
| 5377676 | Vari et al. | Jan 1995 | A |
| 5431170 | Mathews | Jul 1995 | A |
| 5436499 | Namavar et al. | Jul 1995 | A |
| 5456252 | Vari et al. | Oct 1995 | A |
| 5479934 | Imran | Jan 1996 | A |
| 5482036 | Diab et al. | Jan 1996 | A |
| 5494043 | O'Sullivan et al. | Feb 1996 | A |
| 5533511 | Kaspari et al. | Jul 1996 | A |
| 5590649 | Caro et al. | Jan 1997 | A |
| 5602924 | Durand et al. | Feb 1997 | A |
| 5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
| 5638818 | Diab et al. | Jun 1997 | A |
| 5645440 | Tobler et al. | Jul 1997 | A |
| 5671914 | Kalkhoran et al. | Sep 1997 | A |
| 5726440 | Kalkhoran et al. | Mar 1998 | A |
| D393830 | Tobler et al. | Apr 1998 | S |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5747806 | Khalil et al. | May 1998 | A |
| 5750994 | Schlager | May 1998 | A |
| 5758644 | Diab et al. | Jun 1998 | A |
| 5760910 | Lepper, Jr. et al. | Jun 1998 | A |
| 5890929 | Mills et al. | Apr 1999 | A |
| 5919134 | Diab | Jul 1999 | A |
| 5987343 | Kinast | Nov 1999 | A |
| 5997343 | Mills et al. | Dec 1999 | A |
| 6002952 | Diab et al. | Dec 1999 | A |
| 6010937 | Karam et al. | Jan 2000 | A |
| 6027452 | Flaherty et al. | Feb 2000 | A |
| 6040578 | Malin et al. | Mar 2000 | A |
| 6066204 | Haven | May 2000 | A |
| 6115673 | Malin et al. | Sep 2000 | A |
| 6124597 | Shehada et al. | Sep 2000 | A |
| 6128521 | Marro et al. | Oct 2000 | A |
| 6129675 | Jay | Oct 2000 | A |
| 6144868 | Parker | Nov 2000 | A |
| 6152754 | Gerhardt et al. | Nov 2000 | A |
| 6184521 | Coffin, IV et al. | Feb 2001 | B1 |
| 6232609 | Snyder et al. | May 2001 | B1 |
| 6241683 | Macklem et al. | Jun 2001 | B1 |
| 6253097 | Aronow et al. | Jun 2001 | B1 |
| 6255708 | Sudharsanan et al. | Jul 2001 | B1 |
| 6280381 | Malin et al. | Aug 2001 | B1 |
| 6285896 | Tobler et al. | Sep 2001 | B1 |
| 6308089 | von der Ruhr et al. | Oct 2001 | B1 |
| 6317627 | Ennen et al. | Nov 2001 | B1 |
| 6321100 | Parker | Nov 2001 | B1 |
| 6334065 | Al-Ali et al. | Dec 2001 | B1 |
| 6360114 | Diab et al. | Mar 2002 | B1 |
| 6368283 | Xu et al. | Apr 2002 | B1 |
| 6411373 | Garside et al. | Jun 2002 | B1 |
| 6415167 | Blank et al. | Jul 2002 | B1 |
| 6430437 | Marro | Aug 2002 | B1 |
| 6430525 | Weber et al. | Aug 2002 | B1 |
| 6463311 | Diab | Oct 2002 | B1 |
| 6470199 | Kopotic et al. | Oct 2002 | B1 |
| 6487429 | Hockersmith et al. | Nov 2002 | B2 |
| 6505059 | Kollias et al. | Jan 2003 | B1 |
| 6525386 | Mills et al. | Feb 2003 | B1 |
| 6526300 | Kiani et al. | Feb 2003 | B1 |
| 6534012 | Hazen et al. | Mar 2003 | B1 |
| 6542764 | Al-Ali et al. | Apr 2003 | B1 |
| 6580086 | Schulz et al. | Jun 2003 | B1 |
| 6584336 | Ali et al. | Jun 2003 | B1 |
| 6587196 | Stippick et al. | Jul 2003 | B1 |
| 6587199 | Luu | Jul 2003 | B1 |
| 6597932 | Tian et al. | Jul 2003 | B2 |
| 6606511 | Ali et al. | Aug 2003 | B1 |
| 6635559 | Greenwald et al. | Oct 2003 | B2 |
| 6639668 | Trepagnier | Oct 2003 | B1 |
| 6640116 | Diab | Oct 2003 | B2 |
| 6640117 | Makarewicz et al. | Oct 2003 | B2 |
| 6658276 | Kiani et al. | Dec 2003 | B2 |
| 6661161 | Lanzo et al. | Dec 2003 | B1 |
| 6697656 | Al-Ali | Feb 2004 | B1 |
| 6697658 | Ai-Ai | Feb 2004 | B2 |
| RE38476 | Diab et al. | Mar 2004 | E |
| RE38492 | Diab et al. | Apr 2004 | E |
| 6738652 | Mattu et al. | May 2004 | B2 |
| 6760607 | Al-Ali | Jul 2004 | B2 |
| 6788965 | Ruchti et al. | Sep 2004 | B2 |
| 6816241 | Grubisic | Nov 2004 | B2 |
| 6822564 | Al-Ali | Nov 2004 | B2 |
| 6850787 | Weber et al. | Feb 2005 | B2 |
| 6850788 | Al-Ali | Feb 2005 | B2 |
| 6876931 | Lorenz et al. | Apr 2005 | B2 |
| 6920345 | Al-Ali et al. | Jul 2005 | B2 |
| 6934570 | Kiani et al. | Aug 2005 | B2 |
| 6943348 | Coffin IV | Sep 2005 | B1 |
| 6956649 | Acosta et al. | Oct 2005 | B2 |
| 6961598 | Diab | Nov 2005 | B2 |
| 6970792 | Diab | Nov 2005 | B1 |
| 6985764 | Mason et al. | Jan 2006 | B2 |
| 6990364 | Ruchti et al. | Jan 2006 | B2 |
| 6998247 | Monfre et al. | Feb 2006 | B2 |
| 7003338 | Weber et al. | Feb 2006 | B2 |
| 7015451 | Dalke et al. | Mar 2006 | B2 |
| 7027849 | Al-Ali | Apr 2006 | B2 |
| D526719 | Richie, Jr. et al. | Aug 2006 | S |
| 7096052 | Mason et al. | Aug 2006 | B2 |
| 7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
| D529616 | Deros et al. | Oct 2006 | S |
| 7133710 | Acosta et al. | Nov 2006 | B2 |
| 7142901 | Kiani et al. | Nov 2006 | B2 |
| 7225006 | Al-Ali et al. | May 2007 | B2 |
| RE39672 | Shehada et al. | Jun 2007 | E |
| 7230708 | Lapotko et al. | Jun 2007 | B2 |
| 7254429 | Schurman et al. | Aug 2007 | B2 |
| 7254431 | Al-Ali et al. | Aug 2007 | B2 |
| 7254434 | Schulz et al. | Aug 2007 | B2 |
| 7274955 | Kiani et al. | Sep 2007 | B2 |
| D554263 | Al-Ali et al. | Oct 2007 | S |
| 7280858 | Al-Ali et al. | Oct 2007 | B2 |
| 7289835 | Mansfield et al. | Oct 2007 | B2 |
| 7292883 | De Felice et al. | Nov 2007 | B2 |
| 7341559 | Schulz et al. | Mar 2008 | B2 |
| 7343186 | Lamego et al. | Mar 2008 | B2 |
| D566282 | Al-Ali et al. | Apr 2008 | S |
| 7356365 | Schurman | Apr 2008 | B2 |
| 7371981 | Abdul-Hafiz | May 2008 | B2 |
| 7373193 | Al-Ali et al. | May 2008 | B2 |
| 7377794 | Al-Ali et al. | May 2008 | B2 |
| 7395158 | Monfre et al. | Jul 2008 | B2 |
| 7415297 | Al-Ali et al. | Aug 2008 | B2 |
| 7438683 | Al-Ali et al. | Oct 2008 | B2 |
| 7483729 | Al-Ali et al. | Jan 2009 | B2 |
| D587657 | Al-Ali et al. | Mar 2009 | S |
| 7500950 | Al-Ali et al. | Mar 2009 | B2 |
| 7509494 | Al-Ali | Mar 2009 | B2 |
| 7510849 | Schurman et al. | Mar 2009 | B2 |
| 7514725 | Wojtczuk et al. | Apr 2009 | B2 |
| 7519406 | Blank et al. | Apr 2009 | B2 |
| D592507 | Wachman et al. | May 2009 | S |
| 7530942 | Diab | May 2009 | B1 |
| 7593230 | Abul-Haj et al. | Sep 2009 | B2 |
| 7596398 | Al-Ali et al. | Sep 2009 | B2 |
| 7606608 | Blank et al. | Oct 2009 | B2 |
| 7620674 | Ruchti et al. | Nov 2009 | B2 |
| D606659 | Kiani et al. | Dec 2009 | S |
| 7629039 | Eckerbom et al. | Dec 2009 | B2 |
| 7640140 | Ruchti et al. | Dec 2009 | B2 |
| 7647083 | Al-Ali et al. | Jan 2010 | B2 |
| D609193 | Al-Ali et al. | Feb 2010 | S |
| D614305 | Al-Ali et al. | Apr 2010 | S |
| 7697966 | Monfre et al. | Apr 2010 | B2 |
| 7698105 | Ruchti et al. | Apr 2010 | B2 |
| RE41317 | Parker | May 2010 | E |
| RE41333 | Blank et al. | May 2010 | E |
| 7729733 | Al-Ali et al. | Jun 2010 | B2 |
| 7761127 | Al-Ali et al. | Jul 2010 | B2 |
| 7764982 | Dalke et al. | Jul 2010 | B2 |
| D621516 | Kiani et al. | Aug 2010 | S |
| 7791155 | Diab | Sep 2010 | B2 |
| RE41912 | Parker | Nov 2010 | E |
| 7880626 | Al-Ali et al. | Feb 2011 | B2 |
| 7909772 | Popov et al. | Mar 2011 | B2 |
| 7919713 | Al-Ali et al. | Apr 2011 | B2 |
| 7937128 | Al-Ali | May 2011 | B2 |
| 7937129 | Mason et al. | May 2011 | B2 |
| 7941199 | Kiani | May 2011 | B2 |
| 7957780 | Lamego et al. | Jun 2011 | B2 |
| 7962188 | Kiani et al. | Jun 2011 | B2 |
| 7976472 | Kiani | Jul 2011 | B2 |
| 7990382 | Kiani | Aug 2011 | B2 |
| 7999161 | Oraevsky et al. | Aug 2011 | B2 |
| 8008088 | Bellott et al. | Aug 2011 | B2 |
| RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
| 8028701 | Al-Ali et al. | Oct 2011 | B2 |
| 8048040 | Kiani | Nov 2011 | B2 |
| 8050728 | Al-Ali et al. | Nov 2011 | B2 |
| RE43169 | Parker | Feb 2012 | E |
| 8118620 | Al-Ali et al. | Feb 2012 | B2 |
| 8130105 | Al-Ali et al. | Mar 2012 | B2 |
| 8182443 | Kiani | May 2012 | B1 |
| 8190223 | Al-Ali et al. | May 2012 | B2 |
| 8203438 | Kiani et al. | Jun 2012 | B2 |
| 8203704 | Merritt et al. | Jun 2012 | B2 |
| 8219172 | Schurman et al. | Jul 2012 | B2 |
| 8224411 | Al-Ali et al. | Jul 2012 | B2 |
| 8229532 | Davis | Jul 2012 | B2 |
| 8233955 | Al-Ali et al. | Jul 2012 | B2 |
| 8243272 | Adams | Aug 2012 | B2 |
| 8255026 | Ai-Ali | Aug 2012 | B1 |
| 8265723 | McHale et al. | Sep 2012 | B1 |
| 8274360 | Sampath et al. | Sep 2012 | B2 |
| 8280473 | Al-Ali | Oct 2012 | B2 |
| 8315683 | Al-Ali et al. | Nov 2012 | B2 |
| RE43860 | Parker | Dec 2012 | E |
| 8346330 | Lamego | Jan 2013 | B2 |
| 8353842 | Al-Ali et al. | Jan 2013 | B2 |
| 8355766 | MacNeish, III et al. | Jan 2013 | B2 |
| 8374665 | Lamego | Feb 2013 | B2 |
| 8388353 | Kiani et al. | Mar 2013 | B2 |
| 8401602 | Kiani | Mar 2013 | B2 |
| 8414499 | Al-Ali et al. | Apr 2013 | B2 |
| 8418524 | Al-Ali | Apr 2013 | B2 |
| 8428967 | Olsen et al. | Apr 2013 | B2 |
| 8430817 | Al-Ali et al. | Apr 2013 | B1 |
| 8437825 | Dalvi et al. | May 2013 | B2 |
| 8455290 | Siskavich | Jun 2013 | B2 |
| 8457707 | Kiani | Jun 2013 | B2 |
| 8471713 | Poeze et al. | Jun 2013 | B2 |
| 8473020 | Kiani et al. | Jun 2013 | B2 |
| 8509867 | Workman et al. | Aug 2013 | B2 |
| 8515509 | Bruinsma et al. | Aug 2013 | B2 |
| 8523781 | Al-Ali | Sep 2013 | B2 |
| D692145 | Al-Ali et al. | Oct 2013 | S |
| 8571617 | Reichgott et al. | Oct 2013 | B2 |
| 8571618 | Lamego et al. | Oct 2013 | B1 |
| 8571619 | Al-Ali et al. | Oct 2013 | B2 |
| 8577431 | Lamego et al. | Nov 2013 | B2 |
| 8584345 | Al-Ali et al. | Nov 2013 | B2 |
| 8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
| 8630691 | Lamego et al. | Jan 2014 | B2 |
| 8641631 | Sierra et al. | Feb 2014 | B2 |
| 8652060 | Al-Ali | Feb 2014 | B2 |
| 8666468 | Al-Ali | Mar 2014 | B1 |
| 8670811 | O'Reilly | Mar 2014 | B2 |
| RE44823 | Parker | Apr 2014 | E |
| RE44875 | Kiani et al. | Apr 2014 | E |
| 8688183 | Bruinsma et al. | Apr 2014 | B2 |
| 8690799 | Telfort et al. | Apr 2014 | B2 |
| 8702627 | Telfort et al. | Apr 2014 | B2 |
| 8712494 | MacNeish, III et al. | Apr 2014 | B1 |
| 8715206 | Telfort et al. | May 2014 | B2 |
| 8723677 | Kiani | May 2014 | B1 |
| 8740792 | Kiani et al. | Jun 2014 | B1 |
| 8755535 | Telfort et al. | Jun 2014 | B2 |
| 8755872 | Marinow | Jun 2014 | B1 |
| 8764671 | Kiani | Jul 2014 | B2 |
| 8768423 | Shakespeare et al. | Jul 2014 | B2 |
| 8771204 | Telfort et al. | Jul 2014 | B2 |
| 8781544 | Al-Ali et al. | Jul 2014 | B2 |
| 8790268 | Al-Ali | Jul 2014 | B2 |
| 8801613 | Al-Ali et al. | Aug 2014 | B2 |
| 8821397 | Al-Ali et al. | Sep 2014 | B2 |
| 8821415 | Al-Ali et al. | Sep 2014 | B2 |
| 8830449 | Lamego et al. | Sep 2014 | B1 |
| 8840549 | Al-Ali et al. | Sep 2014 | B2 |
| 8852094 | Al-Ali et al. | Oct 2014 | B2 |
| 8852994 | Wojtczuk et al. | Oct 2014 | B2 |
| 8897847 | Ai-Ali | Nov 2014 | B2 |
| 8911377 | Al-Ali | Dec 2014 | B2 |
| 8989831 | Al-Ali et al. | Mar 2015 | B2 |
| 8998809 | Kiani | Apr 2015 | B2 |
| 9066666 | Kiani | Jun 2015 | B2 |
| 9066680 | Al-Ali et al. | Jun 2015 | B1 |
| 9095316 | Welch et al. | Aug 2015 | B2 |
| 9106038 | Telfort et al. | Aug 2015 | B2 |
| 9107625 | Telfort et al. | Aug 2015 | B2 |
| 9131881 | Diab et al. | Sep 2015 | B2 |
| 9138180 | Coverston et al. | Sep 2015 | B1 |
| 9153112 | Kiani et al. | Oct 2015 | B1 |
| 9155497 | Plumley et al. | Oct 2015 | B1 |
| 9192329 | Al-Ali | Nov 2015 | B2 |
| 9192351 | Telfort et al. | Nov 2015 | B1 |
| 9195385 | Al-Ali et al. | Nov 2015 | B2 |
| 9211095 | Ai-Ali | Dec 2015 | B1 |
| 9218454 | Kiani et al. | Dec 2015 | B2 |
| 9245668 | Vo et al. | Jan 2016 | B1 |
| 9267572 | Barker et al. | Feb 2016 | B2 |
| 9277880 | Poeze et al. | Mar 2016 | B2 |
| 9307928 | Al-Ali et al. | Apr 2016 | B1 |
| 9323894 | Kiani | Apr 2016 | B2 |
| D755392 | Hwang et al. | May 2016 | S |
| 9326712 | Kiani | May 2016 | B1 |
| 9392945 | Al-Ali et al. | Jul 2016 | B2 |
| 9408542 | Kinast et al. | Aug 2016 | B1 |
| 9436645 | Al-Ali et al. | Sep 2016 | B2 |
| 9445759 | Lamego et al. | Sep 2016 | B1 |
| 9474474 | Lamego et al. | Oct 2016 | B2 |
| 9480435 | Olsen | Nov 2016 | B2 |
| 9510779 | Poeze et al. | Dec 2016 | B2 |
| 9517024 | Kiani et al. | Dec 2016 | B2 |
| 9532722 | Lamego et al. | Jan 2017 | B2 |
| 9560996 | Kiani | Feb 2017 | B2 |
| 9579039 | Jansen et al. | Feb 2017 | B2 |
| 9622692 | Lamego et al. | Apr 2017 | B2 |
| D788312 | Al-Ali et al. | May 2017 | S |
| 9649054 | Lamego et al. | May 2017 | B2 |
| 9697928 | Al-Ali et al. | Jul 2017 | B2 |
| 9717458 | Lamego et al. | Aug 2017 | B2 |
| 9724016 | Al-Ali et al. | Aug 2017 | B1 |
| 9724024 | Al-Ali | Aug 2017 | B2 |
| 9724025 | Kiani et al. | Aug 2017 | B1 |
| 9749232 | Sampath et al. | Aug 2017 | B2 |
| 9750442 | Olsen | Sep 2017 | B2 |
| 9750461 | Telfort | Sep 2017 | B1 |
| 9775545 | Al-Ali et al. | Oct 2017 | B2 |
| 9778079 | Al-Ali et al. | Oct 2017 | B1 |
| 9782077 | Lamego et al. | Oct 2017 | B2 |
| 9787568 | Lamego et al. | Oct 2017 | B2 |
| 9808188 | Perea et al. | Nov 2017 | B1 |
| 9839379 | Al-Ali et al. | Dec 2017 | B2 |
| 9839381 | Weber et al. | Dec 2017 | B1 |
| 9847749 | Kiani et al. | Dec 2017 | B2 |
| 9848800 | Lee et al. | Dec 2017 | B1 |
| 9861298 | Eckerbom et al. | Jan 2018 | B2 |
| 9861305 | Weber et al. | Jan 2018 | B1 |
| 9877650 | Muhsin et al. | Jan 2018 | B2 |
| 9891079 | Dalvi | Feb 2018 | B2 |
| 9924897 | Abdul-Hafiz | Mar 2018 | B1 |
| 9936917 | Poeze et al. | Apr 2018 | B2 |
| 9955937 | Telfort | May 2018 | B2 |
| 9965946 | Al-Ali et al. | May 2018 | B2 |
| D820865 | Muhsin et al. | Jun 2018 | S |
| 9986952 | Dalvi et al. | Jun 2018 | B2 |
| D822215 | Al-Ali et al. | Jul 2018 | S |
| D822216 | Barker et al. | Jul 2018 | S |
| 10010276 | Al-Ali et al. | Jul 2018 | B2 |
| 10086138 | Novak, Jr. | Oct 2018 | B1 |
| 10111591 | Dyell et al. | Oct 2018 | B2 |
| D833624 | DeJong et al. | Nov 2018 | S |
| 10123729 | Dyell et al. | Nov 2018 | B2 |
| D835282 | Barker et al. | Dec 2018 | S |
| D835283 | Barker et al. | Dec 2018 | S |
| D835284 | Barker et al. | Dec 2018 | S |
| D835285 | Barker et al. | Dec 2018 | S |
| 10149616 | Al-Ali et al. | Dec 2018 | B2 |
| 10154815 | Al-Ali et al. | Dec 2018 | B2 |
| 10159412 | Lamego et al. | Dec 2018 | B2 |
| 10188348 | Al-Ali et al. | Jan 2019 | B2 |
| RE47218 | Al-Ali | Feb 2019 | E |
| RE47244 | Kiani et al. | Feb 2019 | E |
| RE47249 | Kiani et al. | Feb 2019 | E |
| 10205291 | Scruggs et al. | Feb 2019 | B2 |
| 10226187 | Al-Ali et al. | Mar 2019 | B2 |
| 10231657 | Al-Ali et al. | Mar 2019 | B2 |
| 10231670 | Blank et al. | Mar 2019 | B2 |
| RE47353 | Kiani et al. | Apr 2019 | E |
| 10279247 | Kiani | May 2019 | B2 |
| 10292664 | Al-Ali | May 2019 | B2 |
| 10299720 | Brown et al. | May 2019 | B2 |
| 10327337 | Schmidt et al. | Jun 2019 | B2 |
| 10327713 | Barker et al. | Jun 2019 | B2 |
| 10332630 | Al-Ali | Jun 2019 | B2 |
| 10383520 | Wojtczuk et al. | Aug 2019 | B2 |
| 10383527 | Al-Ali | Aug 2019 | B2 |
| 10388120 | Muhsin et al. | Aug 2019 | B2 |
| D864120 | Forrest et al. | Oct 2019 | S |
| 10441181 | Telfort et al. | Oct 2019 | B1 |
| 10441196 | Eckerbom et al. | Oct 2019 | B2 |
| 10448844 | Al-Ali et al. | Oct 2019 | B2 |
| 10448871 | Al-Ali et al. | Oct 2019 | B2 |
| 10456038 | Lamego et al. | Oct 2019 | B2 |
| 10463340 | Telfort et al. | Nov 2019 | B2 |
| 10471159 | Lapotko et al. | Nov 2019 | B1 |
| 10505311 | Al-Ali et al. | Dec 2019 | B2 |
| 10524738 | Olsen | Jan 2020 | B2 |
| 10532174 | Al-Ali | Jan 2020 | B2 |
| 10537285 | Shreim et al. | Jan 2020 | B2 |
| 10542903 | Al-Ali et al. | Jan 2020 | B2 |
| 10555678 | Dalvi et al. | Feb 2020 | B2 |
| 10568553 | O'Neil et al. | Feb 2020 | B2 |
| RE47882 | Al-Ali | Mar 2020 | E |
| 10608817 | Haider et al. | Mar 2020 | B2 |
| D880477 | Forrest et al. | Apr 2020 | S |
| 10617302 | Al-Ali et al. | Apr 2020 | B2 |
| 10617335 | Al-Ali et al. | Apr 2020 | B2 |
| 10637181 | Al-Ali et al. | Apr 2020 | B2 |
| D886849 | Muhsin et al. | Jun 2020 | S |
| D887548 | Abdul-Hafiz et al. | Jun 2020 | S |
| D887549 | Abdul-Hafiz et al. | Jun 2020 | S |
| 10667764 | Ahmed et al. | Jun 2020 | B2 |
| D890708 | Forrest et al. | Jul 2020 | S |
| 10721785 | Al-Ali | Jul 2020 | B2 |
| 10736518 | Al-Ali et al. | Aug 2020 | B2 |
| 10750984 | Pauley et al. | Aug 2020 | B2 |
| D897098 | Ai-Ali | Sep 2020 | S |
| 10779098 | Iswanto et al. | Sep 2020 | B2 |
| 10827961 | Iyengar et al. | Nov 2020 | B1 |
| 10828007 | Telfort et al. | Nov 2020 | B1 |
| 10832818 | Muhsin et al. | Nov 2020 | B2 |
| 10849554 | Shreim et al. | Dec 2020 | B2 |
| 10856750 | Indorf | Dec 2020 | B2 |
| D906970 | Forrest et al. | Jan 2021 | S |
| D908213 | Abdul-Hafiz et al. | Jan 2021 | S |
| 10918281 | Al-Ali et al. | Feb 2021 | B2 |
| 10932705 | Muhsin et al. | Mar 2021 | B2 |
| 10932729 | Kiani et al. | Mar 2021 | B2 |
| 10939878 | Kiani et al. | Mar 2021 | B2 |
| 10956950 | Al-Ali et al. | Mar 2021 | B2 |
| D916135 | Indorf et al. | Apr 2021 | S |
| D917046 | Abdul-Hafiz et al. | Apr 2021 | S |
| D917550 | Indorf et al. | Apr 2021 | S |
| D917564 | Indorf et al. | Apr 2021 | S |
| D917704 | Al-Ali et al. | Apr 2021 | S |
| 10987066 | Chandran et al. | Apr 2021 | B2 |
| 10991135 | Al-Ali et al. | Apr 2021 | B2 |
| D919094 | Al-Ali et al. | May 2021 | S |
| D919100 | Al-Ali et al. | May 2021 | S |
| 11006867 | Al-Ali | May 2021 | B2 |
| D921202 | Al-Ali et al. | Jun 2021 | S |
| 11024064 | Muhsin et al. | Jun 2021 | B2 |
| 11026604 | Chen et al. | Jun 2021 | B2 |
| D925597 | Chandran et al. | Jul 2021 | S |
| D927699 | Al-Ali et al. | Aug 2021 | S |
| 11076777 | Lee et al. | Aug 2021 | B2 |
| 11114188 | Poeze et al. | Sep 2021 | B2 |
| D933232 | Al-Ali et al. | Oct 2021 | S |
| D933233 | Al-Ali et al. | Oct 2021 | S |
| D933234 | Al-Ali et al. | Oct 2021 | S |
| 11145408 | Sampath et al. | Oct 2021 | B2 |
| 11147518 | Al-Ali et al. | Oct 2021 | B1 |
| 11185262 | Al-Ali et al. | Nov 2021 | B2 |
| 11191484 | Kiani et al. | Dec 2021 | B2 |
| D946596 | Ahmed | Mar 2022 | S |
| D946597 | Ahmed | Mar 2022 | S |
| D946598 | Ahmed | Mar 2022 | S |
| D946617 | Ahmed | Mar 2022 | S |
| 11272839 | Al-Ali et al. | Mar 2022 | B2 |
| 11289199 | Al-Ali | Mar 2022 | B2 |
| RE49034 | Al-Ali | Apr 2022 | E |
| 11298021 | Muhsin et al. | Apr 2022 | B2 |
| D950580 | Ahmed | May 2022 | S |
| D950599 | Ahmed | May 2022 | S |
| D950738 | Al-Ali et al. | May 2022 | S |
| D957648 | Ai-Ali | Jul 2022 | S |
| 11382567 | O'Brien et al. | Jul 2022 | B2 |
| 11389093 | Triman et al. | Jul 2022 | B2 |
| 11406286 | Al-Ali et al. | Aug 2022 | B2 |
| 11417426 | Muhsin et al. | Aug 2022 | B2 |
| 11439329 | Lamego | Sep 2022 | B2 |
| 11445948 | Scruggs et al. | Sep 2022 | B2 |
| D965789 | Al-Ali et al. | Oct 2022 | S |
| D967433 | Al-Ali et al. | Oct 2022 | S |
| 11464410 | Muhsin | Oct 2022 | B2 |
| 11504058 | Sharma et al. | Nov 2022 | B1 |
| 11504066 | Dalvi et al. | Nov 2022 | B1 |
| D971933 | Ahmed | Dec 2022 | S |
| D973072 | Ahmed | Dec 2022 | S |
| D973685 | Ahmed | Dec 2022 | S |
| D973686 | Ahmed | Dec 2022 | S |
| D974193 | Forrest et al. | Jan 2023 | S |
| D979516 | Al-Ali et al. | Feb 2023 | S |
| D980091 | Forrest et al. | Mar 2023 | S |
| 11596363 | Lamego | Mar 2023 | B2 |
| 11627919 | Kiani et al. | Apr 2023 | B2 |
| 11637437 | Al-Ali et al. | Apr 2023 | B2 |
| D985498 | Al-Ali et al. | May 2023 | S |
| 11653862 | Dalvi et al. | May 2023 | B2 |
| D989112 | Muhsin et al. | Jun 2023 | S |
| D989327 | Al-Ali et al. | Jun 2023 | S |
| 11678829 | Al-Ali et al. | Jun 2023 | B2 |
| 11679579 | Al-Ali | Jun 2023 | B2 |
| 11684296 | Vo et al. | Jun 2023 | B2 |
| 11692934 | Normand et al. | Jul 2023 | B2 |
| 11701043 | Al-Ali et al. | Jul 2023 | B2 |
| D997365 | Hwang | Aug 2023 | S |
| 11721105 | Ranasinghe et al. | Aug 2023 | B2 |
| 11730379 | Ahmed et al. | Aug 2023 | B2 |
| D998625 | Indorf et al. | Sep 2023 | S |
| D998630 | Indorf et al. | Sep 2023 | S |
| D998631 | Indorf et al. | Sep 2023 | S |
| D999244 | Indorf et al. | Sep 2023 | S |
| D999245 | Indorf et al. | Sep 2023 | S |
| D999246 | Indorf et al. | Sep 2023 | S |
| 11766198 | Pauley et al. | Sep 2023 | B2 |
| D1000975 | Al-Ali et al. | Oct 2023 | S |
| 11803623 | Kiani et al. | Oct 2023 | B2 |
| 11832940 | Diab et al. | Dec 2023 | B2 |
| D1013179 | Al-Ali et al. | Jan 2024 | S |
| 11872156 | Telfort et al. | Jan 2024 | B2 |
| 11879960 | Ranasinghe et al. | Jan 2024 | B2 |
| 11883129 | Olsen | Jan 2024 | B2 |
| D1022729 | Forrest et al. | Apr 2024 | S |
| 11951186 | Krishnamani et al. | Apr 2024 | B2 |
| 11974833 | Forrest et al. | May 2024 | B2 |
| 11986067 | Al-Ali et al. | May 2024 | B2 |
| 11986289 | Dalvi et al. | May 2024 | B2 |
| 11986305 | Al-Ali et al. | May 2024 | B2 |
| 12004869 | Kiani et al. | Jun 2024 | B2 |
| 12014328 | Wachman et al. | Jun 2024 | B2 |
| D1036293 | Al-Ali et al. | Jul 2024 | S |
| D1037462 | Al-Ali et al. | Jul 2024 | S |
| 12029844 | Pauley et al. | Jul 2024 | B2 |
| 12048534 | Vo et al. | Jul 2024 | B2 |
| 12064217 | Ahmed et al. | Aug 2024 | B2 |
| 12066426 | Lapotko et al. | Aug 2024 | B1 |
| D1041511 | Indorf et al. | Sep 2024 | S |
| D1042596 | DeJong et al. | Sep 2024 | S |
| D1042852 | Hwang | Sep 2024 | S |
| 12076159 | Belur Nagaraj et al. | Sep 2024 | B2 |
| 12082926 | Sharma et al. | Sep 2024 | B2 |
| D1044828 | Chandran et al. | Oct 2024 | S |
| 12106752 | Campbell et al. | Oct 2024 | B2 |
| 12114974 | Al-Ali et al. | Oct 2024 | B2 |
| 20010034477 | Mansfield et al. | Oct 2001 | A1 |
| 20010039483 | Brand et al. | Nov 2001 | A1 |
| 20020010401 | Bushmakin et al. | Jan 2002 | A1 |
| 20020058864 | Mansfield et al. | May 2002 | A1 |
| 20020133080 | Apruzzese et al. | Sep 2002 | A1 |
| 20030013975 | Kiani | Jan 2003 | A1 |
| 20030018243 | Gerhardt et al. | Jan 2003 | A1 |
| 20030144582 | Cohen et al. | Jul 2003 | A1 |
| 20030156288 | Barnum et al. | Aug 2003 | A1 |
| 20030212312 | Coffin, IV et al. | Nov 2003 | A1 |
| 20040106163 | Workman, Jr. et al. | Jun 2004 | A1 |
| 20050055276 | Kiani et al. | Mar 2005 | A1 |
| 20050234317 | Kiani | Oct 2005 | A1 |
| 20060073719 | Kiani | Apr 2006 | A1 |
| 20060189871 | Al-Ali et al. | Aug 2006 | A1 |
| 20060241459 | Tai | Oct 2006 | A1 |
| 20070073116 | Kiani et al. | Mar 2007 | A1 |
| 20070180140 | Welch et al. | Aug 2007 | A1 |
| 20070244377 | Cozad et al. | Oct 2007 | A1 |
| 20080064965 | Jay et al. | Mar 2008 | A1 |
| 20080094228 | Welch et al. | Apr 2008 | A1 |
| 20080103375 | Kiani | May 2008 | A1 |
| 20080221418 | Al-Ali et al. | Sep 2008 | A1 |
| 20080247425 | Welford | Oct 2008 | A1 |
| 20090000614 | Carrano | Jan 2009 | A1 |
| 20090036759 | Ault et al. | Feb 2009 | A1 |
| 20090093687 | Telfort et al. | Apr 2009 | A1 |
| 20090095926 | MacNeish, III | Apr 2009 | A1 |
| 20090141997 | Lee et al. | Jun 2009 | A1 |
| 20090247984 | Lamego et al. | Oct 2009 | A1 |
| 20090275813 | Davis | Nov 2009 | A1 |
| 20090275844 | Al-Ali | Nov 2009 | A1 |
| 20090304033 | Ogilvy et al. | Dec 2009 | A1 |
| 20100004518 | Vo et al. | Jan 2010 | A1 |
| 20100030040 | Poeze et al. | Feb 2010 | A1 |
| 20100099964 | O'Reilly et al. | Apr 2010 | A1 |
| 20100121163 | Vestel et al. | May 2010 | A1 |
| 20100222774 | Hegg | Sep 2010 | A1 |
| 20100234718 | Sampath et al. | Sep 2010 | A1 |
| 20100268042 | Wang | Oct 2010 | A1 |
| 20100270257 | Wachman et al. | Oct 2010 | A1 |
| 20110028806 | Merritt et al. | Feb 2011 | A1 |
| 20110028809 | Goodman | Feb 2011 | A1 |
| 20110040197 | Welch et al. | Feb 2011 | A1 |
| 20110082711 | Poeze et al. | Apr 2011 | A1 |
| 20110087081 | Kiani et al. | Apr 2011 | A1 |
| 20110118561 | Tari et al. | May 2011 | A1 |
| 20110137297 | Kiani et al. | Jun 2011 | A1 |
| 20110172498 | Olsen et al. | Jul 2011 | A1 |
| 20110172508 | Chickering, III et al. | Jul 2011 | A1 |
| 20110176127 | Kanda et al. | Jul 2011 | A1 |
| 20110189701 | Kim | Aug 2011 | A1 |
| 20110230733 | Al-Ali | Sep 2011 | A1 |
| 20120046593 | Oraevsky et al. | Feb 2012 | A1 |
| 20120069860 | Inbar | Mar 2012 | A1 |
| 20120123231 | O'Reilly | May 2012 | A1 |
| 20120165629 | Merritt et al. | Jun 2012 | A1 |
| 20120165801 | Bragagna et al. | Jun 2012 | A1 |
| 20120209084 | Olsen et al. | Aug 2012 | A1 |
| 20120226117 | Lamego et al. | Sep 2012 | A1 |
| 20120283524 | Kiani et al. | Nov 2012 | A1 |
| 20130023775 | Lamego et al. | Jan 2013 | A1 |
| 20130041591 | Lamego | Feb 2013 | A1 |
| 20130060147 | Welch et al. | Mar 2013 | A1 |
| 20130096405 | Garfio | Apr 2013 | A1 |
| 20130296672 | O'Neil et al. | Nov 2013 | A1 |
| 20130345921 | Al-Ali et al. | Dec 2013 | A1 |
| 20140012224 | Zhang | Jan 2014 | A1 |
| 20140049190 | Oh | Feb 2014 | A1 |
| 20140120167 | Lapotko et al. | May 2014 | A1 |
| 20140163353 | Razansky et al. | Jun 2014 | A1 |
| 20140166076 | Kiani et al. | Jun 2014 | A1 |
| 20140180160 | Brown et al. | Jun 2014 | A1 |
| 20140182385 | Oh et al. | Jul 2014 | A1 |
| 20140187973 | Brown et al. | Jul 2014 | A1 |
| 20140273188 | Mohan | Sep 2014 | A1 |
| 20140275871 | Lamego et al. | Sep 2014 | A1 |
| 20140275872 | Merritt et al. | Sep 2014 | A1 |
| 20140316217 | Purdon et al. | Oct 2014 | A1 |
| 20140316218 | Purdon et al. | Oct 2014 | A1 |
| 20140323897 | Brown et al. | Oct 2014 | A1 |
| 20140323898 | Purdon et al. | Oct 2014 | A1 |
| 20150005600 | Blank et al. | Jan 2015 | A1 |
| 20150011907 | Purdon et al. | Jan 2015 | A1 |
| 20150072337 | Lapotko | Mar 2015 | A1 |
| 20150073241 | Lamego | Mar 2015 | A1 |
| 20150080754 | Purdon et al. | Mar 2015 | A1 |
| 20150099950 | Al-Ali et al. | Apr 2015 | A1 |
| 20150106121 | Muhsin et al. | Apr 2015 | A1 |
| 20150351841 | Whiteside et al. | Dec 2015 | A1 |
| 20160166185 | Liepmann et al. | Jun 2016 | A1 |
| 20160196388 | Lamego | Jul 2016 | A1 |
| 20160287141 | Sidlesky | Oct 2016 | A1 |
| 20160341747 | Ewert | Nov 2016 | A1 |
| 20160341945 | Ou et al. | Nov 2016 | A1 |
| 20160367173 | Dalvi et al. | Dec 2016 | A1 |
| 20170016827 | Gervais et al. | Jan 2017 | A1 |
| 20170024748 | Haider | Jan 2017 | A1 |
| 20170042488 | Muhsin | Feb 2017 | A1 |
| 20170055896 | Al-Ali | Mar 2017 | A1 |
| 20170173632 | Al-Ali | Jun 2017 | A1 |
| 20170251974 | Shreim et al. | Sep 2017 | A1 |
| 20170311891 | Kiani et al. | Nov 2017 | A1 |
| 20180000351 | Zharov | Jan 2018 | A1 |
| 20180103874 | Lee et al. | Apr 2018 | A1 |
| 20180136193 | Messerschmidt | May 2018 | A1 |
| 20180199871 | Pauley et al. | Jul 2018 | A1 |
| 20180213583 | Al-Ali | Jul 2018 | A1 |
| 20180242926 | Muhsin et al. | Aug 2018 | A1 |
| 20180247353 | Al-Ali et al. | Aug 2018 | A1 |
| 20180247712 | Muhsin et al. | Aug 2018 | A1 |
| 20180256087 | Al-Ali et al. | Sep 2018 | A1 |
| 20180296161 | Shreim et al. | Oct 2018 | A1 |
| 20180300919 | Muhsin et al. | Oct 2018 | A1 |
| 20180310822 | Indorf et al. | Nov 2018 | A1 |
| 20180310823 | Al-Ali et al. | Nov 2018 | A1 |
| 20180317826 | Muhsin et al. | Nov 2018 | A1 |
| 20180326208 | Ingman et al. | Nov 2018 | A1 |
| 20180344228 | Yelin | Dec 2018 | A1 |
| 20180356418 | Capocasale | Dec 2018 | A1 |
| 20190015023 | Monfre | Jan 2019 | A1 |
| 20190117070 | Muhsin et al. | Apr 2019 | A1 |
| 20190200941 | Chandran et al. | Jul 2019 | A1 |
| 20190239787 | Pauley et al. | Aug 2019 | A1 |
| 20190320906 | Olsen | Oct 2019 | A1 |
| 20190345478 | Lapotko et al. | Nov 2019 | A1 |
| 20190374139 | Kiani et al. | Dec 2019 | A1 |
| 20190374173 | Kiani et al. | Dec 2019 | A1 |
| 20190374713 | Kiani et al. | Dec 2019 | A1 |
| 20190388069 | Weber et al. | Dec 2019 | A1 |
| 20200021930 | Iswanto et al. | Jan 2020 | A1 |
| 20200060869 | Telfort et al. | Feb 2020 | A1 |
| 20200111552 | Ahmed | Apr 2020 | A1 |
| 20200113435 | Muhsin | Apr 2020 | A1 |
| 20200113488 | Al-Ali et al. | Apr 2020 | A1 |
| 20200113496 | Scruggs et al. | Apr 2020 | A1 |
| 20200113497 | Triman et al. | Apr 2020 | A1 |
| 20200113520 | Abdul-Hafiz et al. | Apr 2020 | A1 |
| 20200138288 | Al-Ali et al. | May 2020 | A1 |
| 20200138368 | Kiani et al. | May 2020 | A1 |
| 20200163597 | Dalvi et al. | May 2020 | A1 |
| 20200196877 | Vo et al. | Jun 2020 | A1 |
| 20200253474 | Muhsin et al. | Aug 2020 | A1 |
| 20200253544 | Belur Nagaraj et al. | Aug 2020 | A1 |
| 20200275841 | Telfort et al. | Sep 2020 | A1 |
| 20200288983 | Telfort et al. | Sep 2020 | A1 |
| 20200321793 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329983 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329984 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329993 | Al-Ali et al. | Oct 2020 | A1 |
| 20200330037 | Al-Ali et al. | Oct 2020 | A1 |
| 20210022628 | Telfort et al. | Jan 2021 | A1 |
| 20210104173 | Pauley et al. | Apr 2021 | A1 |
| 20210113121 | Diab et al. | Apr 2021 | A1 |
| 20210117525 | Kiani et al. | Apr 2021 | A1 |
| 20210118581 | Kiani et al. | Apr 2021 | A1 |
| 20210121582 | Krishnamani et al. | Apr 2021 | A1 |
| 20210161465 | Barker et al. | Jun 2021 | A1 |
| 20210236729 | Kiani et al. | Aug 2021 | A1 |
| 20210256267 | Ranasinghe et al. | Aug 2021 | A1 |
| 20210256835 | Ranasinghe et al. | Aug 2021 | A1 |
| 20210275101 | Vo et al. | Sep 2021 | A1 |
| 20210290060 | Ahmed | Sep 2021 | A1 |
| 20210290072 | Forrest | Sep 2021 | A1 |
| 20210290080 | Ahmed | Sep 2021 | A1 |
| 20210290120 | Al-Ali | Sep 2021 | A1 |
| 20210290177 | Novak, Jr. | Sep 2021 | A1 |
| 20210290184 | Ahmed | Sep 2021 | A1 |
| 20210296008 | Novak, Jr. | Sep 2021 | A1 |
| 20210330228 | Olsen et al. | Oct 2021 | A1 |
| 20210386382 | Olsen et al. | Dec 2021 | A1 |
| 20210402110 | Pauley et al. | Dec 2021 | A1 |
| 20220026355 | Normand et al. | Jan 2022 | A1 |
| 20220039707 | Sharma et al. | Feb 2022 | A1 |
| 20220053892 | Al-Ali et al. | Feb 2022 | A1 |
| 20220071562 | Kiani | Mar 2022 | A1 |
| 20220096603 | Kiani et al. | Mar 2022 | A1 |
| 20220151521 | Krishnamani et al. | May 2022 | A1 |
| 20220218244 | Kiani et al. | Jul 2022 | A1 |
| 20220287574 | Telfort et al. | Sep 2022 | A1 |
| 20220296161 | Al-Ali et al. | Sep 2022 | A1 |
| 20220361819 | Al-Ali et al. | Nov 2022 | A1 |
| 20220379059 | Yu et al. | Dec 2022 | A1 |
| 20220392610 | Kiani et al. | Dec 2022 | A1 |
| 20230028745 | Al-Ali | Jan 2023 | A1 |
| 20230038389 | Vo | Feb 2023 | A1 |
| 20230045647 | Vo | Feb 2023 | A1 |
| 20230058052 | Ai-Ali | Feb 2023 | A1 |
| 20230058342 | Kiani | Feb 2023 | A1 |
| 20230069789 | Koo et al. | Mar 2023 | A1 |
| 20230087671 | Telfort et al. | Mar 2023 | A1 |
| 20230110152 | Forrest et al. | Apr 2023 | A1 |
| 20230111198 | Yu et al. | Apr 2023 | A1 |
| 20230115397 | Vo et al. | Apr 2023 | A1 |
| 20230116371 | Mills et al. | Apr 2023 | A1 |
| 20230135297 | Kiani et al. | May 2023 | A1 |
| 20230138098 | Telfort et al. | May 2023 | A1 |
| 20230145155 | Krishnamani et al. | May 2023 | A1 |
| 20230147750 | Barker et al. | May 2023 | A1 |
| 20230210417 | Al-Ali et al. | Jul 2023 | A1 |
| 20230222805 | Muhsin et al. | Jul 2023 | A1 |
| 20230222887 | Muhsin et al. | Jul 2023 | A1 |
| 20230226331 | Kiani et al. | Jul 2023 | A1 |
| 20230284916 | Telfort | Sep 2023 | A1 |
| 20230284943 | Scruggs et al. | Sep 2023 | A1 |
| 20230301562 | Scruggs et al. | Sep 2023 | A1 |
| 20230346993 | Kiani et al. | Nov 2023 | A1 |
| 20230368221 | Haider | Nov 2023 | A1 |
| 20230371893 | Al-Ali et al. | Nov 2023 | A1 |
| 20230389837 | Krishnamani et al. | Dec 2023 | A1 |
| 20240016418 | Devadoss et al. | Jan 2024 | A1 |
| 20240016419 | Devadoss et al. | Jan 2024 | A1 |
| 20240047061 | Al-Ali et al. | Feb 2024 | A1 |
| 20240049310 | Al-Ali et al. | Feb 2024 | A1 |
| 20240049986 | Al-Ali et al. | Feb 2024 | A1 |
| 20240081656 | DeJong et al. | Mar 2024 | A1 |
| 20240122486 | Kiani | Apr 2024 | A1 |
| 20240180456 | Al-Ali | Jun 2024 | A1 |
| 20240188872 | Al-Ali et al. | Jun 2024 | A1 |
| 20240245855 | Vo et al. | Jul 2024 | A1 |
| 20240260894 | Olsen | Aug 2024 | A1 |
| 20240267698 | Telfort et al. | Aug 2024 | A1 |
| 20240277233 | Ai-Ali | Aug 2024 | A1 |
| 20240277280 | Al-Ali | Aug 2024 | A1 |
| 20240298920 | Fernkbist et al. | Sep 2024 | A1 |
| 20240306985 | Vo et al. | Sep 2024 | A1 |
| 20240324953 | Telfort | Oct 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 2007104098 | Sep 2007 | WO |
| WO 2013109722 | Jul 2013 | WO |
| WO 2019224822 | Nov 2019 | WO |
| Entry |
|---|
| US 2022/0192529 A1, 06/2022, Al-Ali et al. (withdrawn) |
| US 2024/0016391 A1, 01/2024, Lapotko et al. (withdrawn) |
| Anderson et al., “Optically Guided Controlled Release from Liposomes with Tubable Plasmonic Nanobubbles,” Journal of Controlled Release, vol. 144, Issue 2, Jun. 1, 2010, in 22 pages. |
| Brusnichkin et al., “Determination of Various Hemoglobin Species with Thermal-Lens Spectrometry,” Moscow University Chemistry Bulletin, vol. 64, Issue 1, Feb. 2009, pp. 45-54. |
| Conjusteau et al., “Metallic Nanoparticles as Optoacoustic Contrast Agents for Medical Imaging,” SPIE Proceedings, vol. 6086, Photons Plus Ultrasound: Imaging and Sensing 2006: The Seventh Conference on Biomedical Thermoacoustics, Optoacoustics, and Acousto-optics, Mar. 6, 2006, in 9 pages. |
| Danysh et al., “The MUCI Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation,” Theranostics, 2, No. 8, Ivyspring International Publisher, 2012, pp. 777-787. |
| Lapotko et al., “Clusterization of Nanoparticles During their Interaction with Living Cells,” Nanomedicine, vol. 2, No. 2, Apr. 2007, pp. 241-253. |
| Lapotko et al., “Elimination of Leukemic Cells from Human Transplants by Laser Nano-Thermolysis,” SPIE Proceedings, vol. 6086, Photons Plus Ultrasound: Imaging and Sensing 2006: The Seventh Conference on Biomedical Thermoacoustics, Optoacoustics, and Acousto-optics, Mar. 6, 2006, in 8 pages. |
| Lapotko et al., “Lantcet: Novel Laser Nanotechnology for Graft Purging,” Biology of Blood and Marrow Transplantation, Feb. 2006, in 2 pages. |
| Lapotko et al., “Laser Activated Nanothermolysis of Leukemia Cells Monitored by Photothermal Microscopy,”SPIE Proceedings, vol. 5697, Photons Plus Ultrasound: Imaging and Sensing 2006: The Seventh Conference on Biomedical Thermoacoustics, Optoacoustics, and Acousto-optics, May 5, 2005, pp. 82-89. |
| Lapotko et al., “Laser Heating Diagnoses and Treats Cancerous Cells,” SPIE Newsroom, The International Society for Optical Engineering, 2006, in 3 pages. |
| Lapotko et al., “Method of Laser Activated Nano-Thermolysis for Elimination of Tumor Cells,” Cancer Letters, vol. 239, Issue 1, Jul. 28, 2006, pp. 36-45. |
| Lapotko, “Monitoring of Apoptosis in Intact Single Cells with Photothermal Microscope,” Journal of the International Society for Advancement of Cytometry, vol. 58A, Issue 2, Apr. 2004, pp. 111-119. |
| Lapotko, “Optical Excitation and Detection of Vapor Bubbles Around Plasmonic Nanoparticles,” Optics Express, vol. 17, Issue 4, Feb. 16, 2009, pp. 2538-2556. |
| Lapotko et al., “Photothermal and Photoacoustic Processes in Laser Activated Nano-Thermolysis of Cells,” SPIE Proceedings, vol. 6437, Photons Plus Ultrasound: Imaging and Sensing 2007: The Eighth Conference on Biomedical Thermoacoustics, Optoacoustics, and Acousto-optics, Mar. 2007, in 13 pages. |
| Lapotko et al., “Photothermal Detection of Laser-Induced Damage in Single Intact Cells,” Lasers in Surgery and Medicine, vol. 33, Issue 5, Dec. 2003, pp. 320-329. |
| Lapotko et al., “Photothermal Image Cytometry of Human Neutrophils,” Journal of the International Society for Advancement of Cytometry, vol. 24, Issue 3, Jul. 1, 1996, pp. 198-203. |
| Lapotko et al., “Photothermal Response of Live Cells Depends Upon Cell Metabolic State,” SPIE Proceedings, vol. 4618, Biomedical Optoacoustics III, Jun. 10, 2002, in 8 pages. |
| Lapotko et al., “Photothermal Time-Resolved Imaging of Living Cells,” Lasers in Surgery and Medicine, vol. 31, Issue 1, Jul. 2002, pp. 53-63. |
| Lapotko et al., “Photothermolysis by Laser-Induced Microbubbles Generated Around Gold Nanorod Clusters Selectively Formed in Leukemia Cells,” SPIE Proceedings, vol. 6856, Photons Plus Ultrasound: Imaging and Sensing 2008: The Ninth Conference on Biomedical Thermoacoustics, Optoacoustics, and Acousto-optics, Feb. 28, 2008, in 10 pages. |
| Lapotko, “Plasmonic Nanobubbles as Tunable Cellular Probes for Cancer Theranostics,” Cancers, vol. 3, No. 1, 2011 pp. 802-840. |
| Lapotko, “Plasmonic Nanoparticle-Generated Photothermal Bubbles and their Biomedical Applications,” Nanomedicine, vol. 4, No. 7, Oct. 2009, pp. 813-845. |
| Lapotko, “Nanophotonics and Theranostics: Will Light do the Magic?” Theranostics 2013, vol. 3, Issue 3, pp. 138-140. |
| Lapotko et al., “Nonstationary Heating and Phase Transitions in a Live Cell in Absorption of Laser Radiation,” Heat Transfer Research, vol. 38, Issue 8, Jan. 2007, pp. 695-708. |
| Lapotko et al., “Selective Laser Nano-Thermolysis of Human Leukemia Cells with Microbubbles Generated Around Clusters of Gold Nanoparticles,” Lasers in Surgery and Medicine, vol. 38, Issue 6, Jul. 2006, pp. 631-642. |
| Lapotko, “Therapy with Gold Nanoparticles and Lasers: What Really Kills the Cells?” Nanomedicine, vol. 4, No. 3, Apr. 2009, pp. 253-256. |
| Lukianova-Hleb et al., “All-in-one Processing of Heterogeneous Human Cell Grafts for Gene and Cell Therapy,” Molecular Therapy—Methods & Clinical Development , vol. 3, Article 16012, 2016, in 8 pages. |
| Lukianova-Hleb et al., “Cell-Specific Multifunctional Processing of Heterogeneous Cell Systems in a Single Laser Pulse Treatment,” ACS Nano, vol. 6, Issue 12, Dec. 21, 2012, pp. 10973-10981. |
| Lukianova-Hleb et al., “Cell-Specific Transmembrane Injection of Molecular Cargo with Gold Nanoparticle-Generated Transient Plasmonic Nanobubbles,” Biomaterials, vol. 33, Issue 21, Jul. 2012, pp. 5441-5450. |
| Lukianova-Hleb et al., “Experimental Techniques for Imaging and Measuring Transient Vapor Nanobubbles,” Applied Physics Letters, vol. 101, Dec. 2012, pp. 264102-1-264102-5. |
| Lukianova-Hleb et al., “Generation and Detection of Plasmonic Nanobubbles in Zebrafish,” Nanotechnology, vol. 21, No. 22, Jun. 4, 2010, in 22 pages. |
| Lukianova-Hleb et al., “Hemozoin-Generated Vapor Nanobubbles for Transdermal Reagent and Needle-Free Detection of Malaria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, No. 3, Jan. 21, 2014, pp. 900-905. |
| Lukianova-Hleb et al., “Improved Cellular Specificity of Plasmonic Nanobubbles versus Nanoparticles in Heterogeneous Cell Systems,” PLoS One, vol. 7, Issue 4, Apr. 2012, in 10 pages. |
| Lukianova-Hleb et al., “Intraoperative Diagnostics and Elimination of Residual Micro-Tumours with Plasmonic Nanobubbles,” Nature Nanotechnology, 2015, in 31 pages. |
| Lukianova-Hleb et al., “Influence of Transient Environmental Photothermal Effects on Optical Scattering by Gold Nanoparticles,” Nano Letters, vol. 9, Issue 5, May 2009, pp. 2160-2166. |
| Lukianova-Hleb et al., “Laser Pulse Duration is Critical for the Generation of Plasmonic Nanobubbles,” Langmuir, vol. 30, Issue 25, 2014, pp. 7425-7434. |
| Lukianova-Hleb et al., “Malaria Theranostics Using Hemozoin-Generated Vapor Nanobubbles,” Theranostics, vol. 4, Issue 7, 2014, pp. 761-769. |
| Lukianova-Hleb et al., “Multifunctional Cell Processing with Plasmonic Nanobubbles,” International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering, vol. 7, No. 11, 2013, pp. 677-681. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles Enhance Efficacy and Selectivity of Chemotherapy Against Drug-Resistant Cancer Cells,” Advanced Materials, vol. 24, Issue 28, Jul. 24, 2012, pp. 3831-3837. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles for Intracellular Targeting and Gene Therapy,” NTSI-Nanotech 2011, vol. 3, pp. 291-294. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles as Transient Vapor Nanobubbles Generated Around Plasmonic Nanoparticles,” ACS Nano, vol. 4, Issue 4, Apr. 27, 2010, pp. 2109-2123. |
| Lukianova-Hleb et al., “Plasmonic Nanobubble-Enhanced Endosomal Escape Processes for Selective and Guided Intracellular Delivery of Chemotherapy to Drug-Resistant Cancer Cells,” Biomaterials, vol. 33, Issue 6, Feb. 2012, pp. 1821-1826. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles Rapidly Detect and Destroy Drug-Resistant Tumors,” Theranostics, vol. 2, No. 10, 2012, pp. 976-787. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles for Cell Theranostic,” Proceedings of SPIE, 2012, vol. 8234, pp. 82341F-1-82341F-10. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles as Tunable Theranostic Agents,” NSTI-Nanotech 2011, vol. 3, pp. 367-370. |
| Lukianova-Hleb et al., “Plasmonic Nanobubbles: Tunable and Transient Probes for Cancer Diagnosis, Therapy and Theranostics,” NSTI-Nanotech 2010, vol. 3, 2010 in 5 pages. |
| Lukianova-Hleb et al., “Rainbow Plasmonic Nanobubbles: Synergistic Activation of Gold Nanoparticle Clusters,” Journal of Nanomedicine & Nanotechnology, vol. 2, Issue 104, Jan. 1, 2011, in 21 pages. |
| Lukianova-Hleb et al., “Safety and Efficacy of Quadrapeutics Versus Chemoradiation in Head and Neck Carcinoma Xenograft Model,” American Journal of Cancer Research, vol. 5, Issue 12, 2015, pp. 3534-3547. |
| Lukianova-Hleb et al., “Selective Gene Transfection of Individual Cells In Vitro with Plasmonic Nanobubbles,” Journal of Controlled Release, vol. 152, Issue 2, Jun. 10, 2011, pp. 286-293. |
| Lukianova-Hleb et al., “Selective and Self-Guided Micro-Ablation of Tissue with Plasmonic Nanobubbles,” Journal of Surgical Research, vol. 166, Issue 1, Mar. 2011, pp. e3-e13. |
| Lukianova-Hleb et al., “Short Laser Pulse-Induced Irreversible Photothermal Effects in Red Blood Cells,” Lasers in Surgery and Medicine, vol. 43, Issue 3, Mar. 2011, pp. 249-260. |
| Lukianova-Hleb et al., “Transdermal Diagnosis of Malaria Using Vapor Nanobubbles,” Emerging Infectious Diseases, vol. 21, No. 7, Jul. 2015, pp. 1122-1127. |
| Lukianova-Hleb et al., “Transient Enhancement and Spectral Narrowing of the Photothermal Effect of Plasmonic Nanoparticles Under Pulsed Excitation,” Advanced Materials, vol. 25, Issue 5, Feb. 6, 2013, pp. 772-776. |
| Lukianova-Hleb et al., “Transient Photothermal Spectra of Plasmonic Nanobubbles,” Langmuir, vol. 28, Issue 10, Feb. 2012, pp. 4858-4866. |
| Lukianova-Hleb et al., “Tunable Plasmonic Nanobubbles for Cell Theranostics,” Nanotechnology, vol. 21, No. 8, Feb. 26, 2010, in 19 pages. |
| Lukianova-Hleb et al., “Tunable Plasmonic Nanoprobes for Theranostics of Prostate Cancer,” Theranostics, vol. 1, 2011, pp. 3-17. |
| Potkin et al., “The Influence of Heterocyclic Compound-Pamam Dendrimer Complexes on Evoked Electrical Responses in Slices of Hypoxic Brain Tissue,” Cellular & Molecular Biology Letters, vol. 19, 2014, pp. 243-248. |
| Vasiliev et al., “Bubble Generation in Micro-Volumes of ‘nonofluids’,” International Journal of Heat and Mass Transfer, vol. 52, Issues 5-6, Feb. 2009, pp. 1534-1539. |
| Choi et al., A High Throughput Microelectroporation Device to Introduce a Chimeric Antigen Receptor to Redirect the Specificity of Human T Cells, Biomed Microdevice, 2010, 12, pp. 855-863. |
| Number | Date | Country | |
|---|---|---|---|
| 62888060 | Aug 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16992596 | Aug 2020 | US |
| Child | 18545276 | US |
